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ABSTRACT 
Mushrooms are known as a powerful source of bioactive compounds including 
antioxidants, inhibitors of human tumour cell lines growth, inducers of apoptosis and 
enhancers of immunity. Indeed, many pre-clinical studies have been conducted in human 
tumour cell lines and in some cases a number of compounds isolated from mushrooms 
have followed to clinical trials. The Northeast of Portugal is one of the European regions 
with higher wild mushrooms diversity. However, to our knowledge, no studies had been 
conducted so far to verify their bioactivities.  
The main aim of this work was the evaluation of the bioactive properties (antioxidant 
properties and growth inhibitory potential on human tumour cell lines) of wild edible 
mushrooms collected in the Northeast of Portugal. 
Once properly identified, methanolic, ethanolic and boiling water extracts were 
prepared from thirty eight wild mushroom species collected in that region. Chemical 
characterization was obtained by high performance liquid chromatography (HPLC) 
coupled to a photodiode array detector (DAD) or to a refraction index detector (RI). 
Antioxidant activity assays were carried out in those extracts, including evaluation of 2,2-
diphenyl-1-picrylhydrazyl (DPPH) radicals scavenging capacity, reducing power and 
inhibition of β-carotene bleaching. Extract-induced cell growth inhibition was assessed 
with the sulforhodamine B assay in four human tumour cell lines (NCI-H460 - lung 
cancer, MCF-7 -breast cancer, HCT-15 -colon cancer and AGS - gastric cancer). The effects 
on cell cycle profile and apoptosis were evaluated by flow cytometry and the effect on the 
expression levels of proteins related to cell cycle and apoptosis was further investigated by 
Western blotting. 
Three wild edible mushroom species revealed growth inhibitory activity in the studied 
human tumour cell lines: Clitocybe alexandri ethanolic extract, Lepista inversa 
methanolic extract and Suillus collinitus methanolic extract. C. alexandri ethanolic extract 
induced an S-phase cell cycle arrest and increased the percentage of apoptotic cells, in the 
NCI-H460 cell line. 
The analysed mushroom species also provided interesting antioxidant potential, mainly 
the boiling water extract of L. inversa which showed the highest DPPH radical scavenging 
activity, reducing power and β-carotene bleaching inhibition.  
S. collinitus methanolic extract induced a slight increase in the number of cells in G1, 
with a concomitant decrease in the percentage of cells in the S phase of the cell cycle and 
an increase in the percentage of apoptotic cells, in the MCF-7 cell line. The combined use 
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of the S. collinitus methanolic extract and etoposide caused a greater decrease in the 
percentage of cell growth, when compared to either of them used individually, indicating 
the potential benefit of this combination. 
The tested extracts were chemically characterized and protocatechuic, p-
hydroxybenzoic, p-coumaric and cinnamic acids were the main compounds identified on 
the phenolic (methanolic and ethanolic) extracts, while mannitol, trehalose and arabinose 
were the main sugars found in the polysaccharidic (boiling water) extracts after hydrolysis.  
The individual compounds identified in the extracts were submitted to a screening of 
tumour cells growth inhibitory activity, but only the phenolic acids and a related 
compound, cinnamic acid, presented activity. This compound was found to be the most 
potent one regarding cell growth inhibition in the NCI-H460 cell line.   
The effect of the individual and combined treatment with the identified compounds was 
also evaluated. Cinnamic and protochatequic acids caused a statistically significantly 
reduction in the number of viable cells. In addition, p-hydroxybenzoic acid did not show 
any significantly reduction in the viable cell number. Nevertheless, it was verified that the 
concomitant use of the three compounds provided the strongest decrease in the viable cell 
number, suggesting a possible concomitant effect of those compounds. 
Overall, the present work has contributed to further understand the bioactive potential 
of wild edible mushrooms from the Northeast of Portugal. This study allowed to identify 
some species with antioxidant or tumour cell growth inhibitory potential.  
 
Keywords: Wild mushrooms, chemical characterization, antioxidant activity, antitumour 
activity, cell cycle, apoptosis. 
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RESUMO 
Os cogumelos são conhecidos como uma poderosa fonte de compostos bioativos, 
incluindo antioxidantes, inibidores de crescimento de linhas celulares tumorais humanas, 
indutores de apoptose e imunoestimuladores. Já foram realizados vários estudos pré-
clínicos em linhas celulares tumorais humanas e alguns compostos isolados de cogumelos 
estão em fase de ensaios clínicos.  
O Nordeste de Portugal é uma das regiões Europeias com maior diversidade de 
cogumelos silvestres. No entanto, até agora não existiam estudos que verificassem as suas 
propriedades bioativas. 
O objetivo principal deste trabalho foi a avaliação das propriedades bioativas 
(propriedades antioxidantes e potencial inibitório de crescimento de linhas celulares 
tumorais humanas) de cogumelos silvestres comestíveis colhidos no Nordeste de Portugal. 
Uma vez devidamente identificados, prepararam-se extratos metanólicos, etanólicos e 
aquosos a partir de trinta e oito espécies de cogumelos silvestres colhidas nessa região. A 
caracterização química foi efetuada por cromatografia líquida de alta eficiência (HPLC) 
acoplada a um detetor de díodos (DAD) ou a um detetor de índice de refração (RI). Os 
ensaios de atividade antioxidantes, realizados nestes extratos, incluíam a avaliação da 
atividade captadora de radicais 2,2-difenil-1-picril-hidrazilo (DPPH), poder redutor e 
inibição da descoloração do β-caroteno. A inibição do crescimento celular foi avaliada com 
o ensaio Sulforrodamina B em quatro linhas celulares tumorais humanas (NCI-H460 - 
pulmão, MCF-7- mama, HCT-15 - cólon e AGS - gástrico). Os efeitos sobre o perfil do ciclo 
celular e apoptose foram avaliados por citometria de fluxo e o efeito sobre os níveis de 
expressão de proteínas relacionadas com ciclo celular e apoptose celular, foi investigado 
por Western blotting. 
Três espécies de cogumelos silvestres comestíveis revelaram atividade inibitória do 
crescimento de linhas celulares tumourais humanas. O extrato etanólico de Clitocybe 
alexandri, o extrato metanólico de Lepista inversa e o extrato metanólico de Suillus 
collinitus revelaram ser os mais potentes. 
O extrato etanólico de C. alexandri induziu uma paragem do ciclo celular em fase S e 
promoveu um aumento da percentagem de células apoptóticas, na linha celular tumoural 
humana de pulmão testada. 
As espécies de cogumelos analisadas também revelaram um interessante potencial 
antioxidante, principalmente o extrato aquoso de L. inversa que apresentou a maior 
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atividade captadora de radicais DPPH, poder redutor e inibição da descoloração do β-
caroteno. 
O extrato metanólico de S. collinitus induziu um ligeiro aumento no número de células 
em G1, com uma concomitante diminuição na percentagem de células na fase S do ciclo 
celular e um aumento na percentagem de células apoptóticas na linha celular tumoural 
humana de mama testada. O uso combinado do extrato metanólico de S. collinitus e de 
etoposideo causou uma maior diminuição na percentagem de crescimento celular, quando 
comparado com qualquer um deles usados individualmente, indicando o potencial 
benefício desta combinação. 
Os extratos testados foram caracterizados quimicamente, tendo sido os ácidos 
protocatéquico, p-hidroxibenzóico, p-cumárico e cinâmico os principais compostos 
identificados nos extratos fenólicos (metanólico e etanólico), enquanto o manitol, a 
trealose e a arabinose foram os principais açúcares encontrados no extrato polissacarídico 
(aquoso), após hidrólise. 
Os compostos individuais identificados nos extractos foram submetidos a uma 
avaliação da atividade inibitória de crescimento celular, mas apenas os ácidos fenólicos e 
um composto relacionado, o ácido cinâmico, apresentaram atividade. Este composto foi o 
mais potente em relação ao efeito de inibição de crescimento celular, na linha celular 
tumoural humana NCI-H460. 
O efeito do tratamento individual e combinado dos compostos identificados também foi 
avaliado. Os ácidos cinâmico e protocatéquico causaram uma redução estatisticamente 
significativa no número de células viáveis. Por sua vez, o ácido p-hidroxibenzóico não 
demonstrou qualquer efeito sobre as células testadas. No entanto, verificou-se que a 
utilização simultânea dos três compostos promoveu uma diminuição substancial no 
número de células viáveis, sugerindo um possível efeito concomitante dos referidos 
compostos. 
Concluindo, o presente trabalho contribuiu para uma melhor compreensão do 
potencial bioativo de cogumelos silvestres comestíveis do Nordeste de Portugal. Este 
estudo permitiu identificar algumas espécies com propriedades antioxidantes ou 
inibitórias do crescimento de células tumourais. 
 
 
Palavras- chave: Cogumelos silvestres; caracterização química; atividade antioxidante; 
atividade antitumoural; ciclo celular; apoptose. 
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1. FUNGI  
Fungi are nowadays known scientifically as an individual group of organisms, but 
had for long been classified as plants. It was only in 1969 that Whittaker reclassified 
these organisms into a separate kingdom, the Fungi. Fungi were then divided in two 
groups, according to their size, the Micromycetes, for microscopic species and the 
Macromycetes or Macrofungi, which included all those which are avidly collected by 
enthusiasts in the woods and fields (Whittaker, 1969). Mushroom is “a macrofungus 
with a distinctive fruiting body, which can be hypogeous or epigeous, large enough to 
be seen with the naked eye and to be picked by hand”. In fact, the fruiting body of the 
fungus is the structure, which is called mushroom, while mycelium is the vegetative 
part comprising a system of branching threads and cordlike stands, which could 
produce the fruiting body under favourable conditions (Chang, 2008).  
Although mycology has been classically considered a branch of botany, there is 
evidence that the kingdom Fungi is more closely related to Animalia than to Plantae. 
Both animals and fungi have chitinous structures, storage of glycogen, and 
mitochondrial codon UGA encoding tryptophan, among other phylogenetic features 
(Nikoh et al., 1994). 
True Fungi (Mycota or Eumycota) have general characteristics that justify their 
classification as a separate kingdom: they are all eukaryotic, most are filamentous with 
individual cells constituting filaments called hyphae. Hyphae grow apically and branch 
to form a network referred to as mycelium. Some, like yeast, are unicellular. Fungi cells 
are surrounded by a cell wall, containing chitin and glucans and their nuclei are mainly 
haploid with cells often multinucleate. Reproduction can be both sexual and assexual 
resulting in spore production. From the metabolic point of view, they are all 
achlorophyllous and though incapable of photosynthesis being chemoheterotrophic 
(chemo-organotrophic). They possess a characteristic range of storage compounds like 
trehalose, glycogen, sugar alcohols and lipids. In terms of ecology, they can be free-
living organims or may form intimate relationships with other organisms (plant roots_-
mycorrhizae, algae - lychen, other fungi) and they can establish all types of trophic 
relations, being saprobiotic, parasitic or symbiotic (Hibbet, 2007). 
Prior classification systems of Fungi based on morphology were updated to more 
accurately reflect phylogenetic relationships determined by molecular tools (Hibbet, 
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2007). Fungi with non-septate or irregularly septate hyphae and thick-walled spores 
were traditionally placed in the phylum Zygomycota. However, evidence for a 
monophyletic Zygomycota is lacking (Seif et al., 2005), and Hibbett (2007) proposed 
the separation of the Zygomycota into four unordered subphyla 
(Entomophthoromycotina, Kickxellomycotina, Mucoromycotina, Zoopagomycotina). 
The separation of the arbuscular mycorrhizal fungi (that lack septa in hyphae but also 
lack zygospores) into the phylum Glomeromycota has been proposed by Schüßler et al. 
(2001). 
The morphological characters shared between Basidiomycota and Ascomycota 
such as regularly septate hyphae and a dikaryotic stage (two separate and different 
nuclei in a single hyphal segment) in the life cycle usually has been interpreted as 
support for a close relationship between both taxa. Numerous phylogenetic studies 
such as SSU rDNA (Berbee and Taylor, 1992), RNA polymerase genes (Liu et al., 2006), 
and mitochondrial genome sequencing (Seif et al., 2005) provide strong support for 
this relationship. A subkingdom desiganted Dikarya is proposed (Hibbett, 2007), 
creating a division between the two well defined phyla (Basidiomycota and 
Ascomycota) and the remaining early diverging lineages whose relationships are not 
precisely known. 
 
 
 
 
 
 
 
Basidiomycota is one of two large phyla that, together with the Ascomycota, 
comprise the subkingdom Dikarya (often referred to as the "higher fungi") within the 
Figure 1. Phylogeny of Kingdom Fungi according to Hibbett et al., 2007 [adapted from (Balckwell et al. 
2012).  
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kingdom Fungi. The number of mushroom species on earth is estimated to be 140,000, 
but only 10% are already known. Assuming that the proportion of useful mushrooms 
among the undiscovered and unexamined mushrooms will be only 5% (an estimated 
small % which seems logical), this implies that there may exist 7,000 yet undiscovered 
species of possible benefit to mankind (Hawksworth, 2001). 
The Basidiomycota contains about 30,000 described species, which is 37% of the 
described species of true Fungi (Kirk et al. 2001). The most conspicuous and familiar 
Basidiomycota are those that produce mushrooms, which are sexual reproductive 
structures. The Basidiomycota also includes yeasts, single-celled forms (Fell et al. 
2001) and asexual species. Basidiomycota are found in virtually all terrestrial 
ecosystems, as well as freshwater and marine habitats (Kohlmeyer and Kohlmeyer, 
1979; Hibbett and Binder, 2001). They are unicellular or multicellular, sexual or 
asexual, and terrestrial or aquatic and so variable that it is impossible to identify any 
morphological characteristics that are both unique to the group and constant in the 
group. Their most diagnostic feature is the production of basidia, which are the cells on 
which sexual spores are produced, and from which the group takes its name. A long-
lived dikaryon, in which each cell in the thallus contains two haploid nuclei resulting 
from a mating event, is another characteristic feature. Finally, clamp connections are a 
kind of hyphal outgrowth that is unique to Basidiomycota, although they are not 
present in all of them (Swann and Hibbett, 2007). 
The Agaricomycotina is one of three major clades of Basidiomycota (with 
Pucciniomycotina and Ustilaginomycotina). The Agaricomycotina contains about 
20,000 species already described, which is almost 70% of the know Basidiomycota 
(Hibbett, 2007). About 98% of the species of the Agaricomycotina are in the clade 
Agaricomycetes, which includes mushrooms, bracket fungi, puffballs, and others. 
Tremellomycetes and Dacrymycetes are the other major groups (Hibbett, 2007). 
Agaricomycetes contains approximately 16,000 described species, which is 98% of the 
described species in the Agaricomycotina (Kirk et al., 2001). Agaricomycetes produce 
mushrooms, and are therefore the most familiar and conspicuous of all Fungi. Other 
Fungi also produce macroscopic fruiting bodies, but the diversity of forms in the 
Agaricomycetes is unmatched (Hibbett, 2007). 
Fruiting bodies of Agaricomycetes range from millimeter-scale, to the giant 
polypores (Burdsall et al., 1996). Agaricomycetes include not only the largest fruiting 
bodies in Fungi, but perhaps the largest and oldest individuals in any group of 
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organisms. Agaricomycetes act as decayers, pathogens, parasites, and mutualistic 
symbionts of both plants and animals. They make their broadest ecological impacts 
through their activities as wood-decayers and ectomycorrhizal symbionts of forest trees 
(such as pines, oaks, dipterocarps, and eucalypts; Rayner and Boddy, 1988; Smith and 
Read, 1997). Agaricomycetes are widespread in virtually all terrestrial ecosystems 
(Hibbett, 2007). 
Agaricomycetes include the majority of the edible mushrooms (although truffles 
and morels are Ascomycota). Cultivated edible Agaricomycetes are decayers that have 
been domesticated, such as button mushrooms (Agaricus bisporus), shiitake 
(Lentinula edodes), oyster mushrooms (Pleurotus ostreatus), and others. Most of the 
wild-collected edible species are mycorrhizal and (this makes them difficult or quite 
impossible to cultivate) such as porcini (Boletus edulis), chanterelles (Cantharellus 
cibarius), and matsutake (Tricholoma matsutake). Some species of Agaricomycetes 
produce secondary metabolites that make them toxic or hallucinogenic (or 
bioluminescent) (Hibbett, 2007).  Furthermore, approximately 700 species of higher 
Agaricomycetes have been already found to possess significant pharmacological 
activities (Mizuno, 1995; Wasser, 2002).  
Since ancient times many mankind cultures have used mushrooms as both food 
and medicine. Nowadays, the fruiting body of edible mushrooms is usually the material 
which is collected and consumed as food but several types of products, from fruiting 
bodies to mycelia, are commercialized as dietary supplements given their potential 
therapeutic effects, and/or consumed in the form of capsules, tablets or extracts (Chang 
and Buswell, 2003). Recently, these fungi have been considered as having a potential 
market as functional foods. At the same time, some species are greatly appreciated for 
their extremely high value in gourmet cooking (Chang, 2008). 
1.1  NUTRITIONAL PROPERTIES  
Edible mushrooms are widely consumed in many countries as food. Given their 
attractive taste, aroma and nutritional values, edible mushrooms are valuable components 
of the diet. Their culinary and commercial value is mainly due to their organoleptic 
properties such as their texture and flavour, being possible to distinguish edible 
mushroom species on the basis of their characteristic odor or aroma (De Pinho et al., 
2008; Kalac, 2009; Zawirska-wojtasiak et al., 2009).  
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Edible mushrooms are essentially constituted by water (81.8 to 94.8%). This 
variability is related to the mushroom species and to the harvest, growth, cooking and 
storage conditions. Due to the high moisture content, fresh edible mushrooms have a 
short shelf life, therefore the consumption of wild edible mushrooms throughout the year  
is not possible unless an appropriate storage processing is performed (Kalac, 2009; 
Guillamón et al., 2010).  
Their important nutritional value has been attributed to high protein, fiber, vitamin, 
mineral, carbohydrates and water contents and to low-fat levels.  
In general, mushrooms are quite rich in protein, having an important content of 
essential amino acids (Mattilda et al., 2001). The amino acids composition of mushroom 
proteins are comparable to animal proteins (Flegg and Maw, 1997; Gruen and Wong, 
1982; Kalac, 2009). 
For example, the protein content found in mushrooms may vary from 15.2 g/100 g dry 
weight (dw) in Lentinus edodes to 80.93 g/100 g dw in Agaricus bisporus (Manzi et al., 
1999). The levels of essential amino acids in mushrooms have been reported to vary widely 
among species (Manzi et al., 1999; Guillamón et al., 2010). According to FAO/WHO, they 
are considered rich in glutamic acid, aspartic acid and arginine. However, their proteins 
are deficient in methionine and cysteine (Manzi et al., 1999). It is believed that the 
consumption of mushrooms will have a tendency to increase in coming years, precisely 
because they are an important source of proteins and amino acids that might replace 
animal proteins, thereby reducing the risks associated with its use in the human diet 
(Kalac, 2009).  
Mushrooms are also a rich source of numerous dietary fibers. In general, a 
remarkably high or appreciable level of total fiber ranging from 5.5 to 42.6 g/100g dw was 
obtained from the Boletus group, Agrocybe aegerita, Agaricus bisporus, Pleurotus 
eryngii and ostreatus, in which β-glucans are the major fiber polysaccharides together 
with chitin (Manzi et al., 2001; Manzi et al., 2004). Dietary fiber in mushrooms shows 
higher levels of insoluble dietary fiber (2.28–8.99 g/100 g edible weight) than soluble 
dietary fiber (0.32–2.20 g/100 g edible weight) (Manzi et al., 2000; Manzi et al., 2004). 
The β-glucans represent from 4 to 13% of the total dietary fiber, depending on mushrooms 
species (Kalac, 2009).  
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The range of reported concentrations of carbohydrates varies from 35 to 70% dw. 
Nonetheless, despite the different profile of sugars among species, mannitol and trehalose 
are the main sugars in many analyzed mushrooms. For example in Lactarius deliciosus, 
Chantarellus cibarius, Agaricus bisporus and Volvariella volvacea, mannitol was the 
most abundant sugar, while trehalose predominates in Pleurotus ostreatus, Boletus edulis, 
Lepista nuda and Calocybe gambosa. Other sugars only occur either in small amounts or 
remain undetected (Bano and Rajarathnam, 1988; Longvah and Deosthale, 1998; Díez and 
Alvarez, 2001; Manzi et al., 2004; Barros et al., 2007; Barros et al., 2008b). 
Furthermore, these fungi have a nutritionally significative content of vitamins (B1, B2, 
B12, C and D) and mineral elements (Ca, K, Mg, Na, P, Cu, Fe, Mn and Se). Indeed, 
mushrooms are a good source of vitamins, based on the high levels of riboflavin (vitamin 
B2), niacin and folates and traces of vitamin C, vitamin B1, vitamin D, β-carotene 
(precursor of vitamin A), vitamin E and vitamin B12 (Mattilda et al., 2001; Heleno et al. 
2010). Mushrooms appear as the only non-animal-based food source containing vitamin 
D, and hence they are the only natural vitamin D source for vegetarians. Indeed, vitamin 
D2 content is considerable in a number of wild mushroom species, but unfortunately is 
almost absent in cultivated species (Mattila et al., 1994; Mattilda et al., 2001).  
As compared with vegetables, mushrooms proved to provide a reasonable content of 
many mineral elements (6–10.5% dw). The main constituents in the ash are potassium 
and, depending on the mushroom, phosphorus or magnesium, in addition to calcium, 
copper, iron and zinc (Mattilda et al. 2001). 
Dietary mushrooms provide low amounts of fat. Generally, unsaturated fatty acids are 
predominant over saturated fatty acids especially palmitic acid (C16:0), oleic acid (C18:1) 
and linoleic acid (C18:2) (Longvah and Deosthale, 1998; Barros et al., 2007). The 
remaining fatty acids are only found in small amounts, except in the case of the Lactarius 
species which contains an abundant amount of stearic acid (C18:0) (Barros et al., 2007; 
Heleno et al., 2009). Linolenic acid (C18:3) is the precursor for 1-octen-3-ol (also known 
as mushroom alcohol), the principal aromatic compound in most fungi, which 
characteristically and distinctively contributes to mushrooms flavour (Maga, 1981). 
With no doubt, edible mushrooms in fresh, cooked or processed forms are a 
nutritionally sound and tasteful food source for most people and can be a significant 
dietary component for vegetarians (Breene, 1990). 
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1.2 MEDICINAL PROPERTIES 
In addition to being nutrient-rich foods and quite tasty, edible mushrooms have been 
known to be a source of bioactive products (Hobbs, 1995). 
In this context, edible mushrooms can be considered as a functional food. The 
International Life Sciences Institute (ILSI Europe), states that "a food can be considered 
as "functional" if it is satisfactorily shown to affect beneficially one or more target 
functions in the body, beyond adequate nutritional effects, in a way that is relevant to both 
a better state of health and welfare and/or reduction of disease risk" (Thomas and Earl, 
1994; Diplock et al., 1999). However, food as medicine reinforces the paradigm of 
functional foods. Functional foods cannot claim to cure diseases but, increasingly, 
evidence is being produced that supports the role of some functional foods in disease 
prevention (Jones and Jew, 2007; Sirò et al., 2008). 
Wild mushrooms can be found in old books of traditional medicine, especially in the 
Orient, as specific pharmacological agents (Hobbs, 1995). Almost all important medicinal 
mushrooms are under a large-scale artificial cultivation (Smith, 1972). According to the 
definition of functional food by the International Life Sciences Institute in Europe 
(Diplock et al., 1999), the mushroom is now gaining worldwide recognition as a functional 
food concerning improvement, prevention or treatment of some diseases (Mattilda et al., 
2000; Cheung, 2008). 
Functional food science is now considered as a part of nutritional science, in which 
the primary objectives are to maintain good health, improve homeostasis and to create the 
conditions for disease risk reduction. In this way it could be seen to be quite distinct from 
the medical and pharmaceutical sciences, where the objectives are mainly to cure or 
control diseases (Diplock et al., 1998; Saris, 1998). 
Several studies have been published in which different species of fungi have shown 
potential in the prevention and treatment of a number of human diseases (Wasser and 
Weis, 1999a; Chang, 2008; Ferreira et al., 2009; Ferreira et al., 2010; Guillamón et al., 
2010; Xu et al., 2011). 
In Asian countries, like China and Japan, mushrooms such as Lingzhi (Ganoderma 
lucidum), Shiitake (Lentinus edodes), and Yiner (Tremella fuciformis) that have been 
collected, cultivated and used for hundreds of years, are being evaluated as edible and 
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medicinal resources. Indeed, most traditional knowledge about the mushrooms as food 
and medicinal agents comes from these species (Hobbs, 1995; Miles and Chang, 1997; 
Wasser, 2002).  
Several genus of mushrooms are known to have various therapeutic properties, for 
example genus species like Lentinus (Lentinula), Auricularia, Hericium, Grifola, 
Flammulina, Pleurotus, Tremella, Ganoderma and Trametes (Coriolus) (Wasser and 
Weis, 1999).  
As a result of the large numbers of scientific studies that have been conducted on 
medicinal mushrooms, different bioactive compounds of edible mushrooms have been 
discovered. These compounds (both cellular components and secondary metabolites) are 
responsible for several activities, such as: 
- antioxidant (Mau et al., 2002; Lo and Cheung, 2005; Barros et al., 2007; Ferreira et 
al., 2007; Barros et al., 2008b;  Ferreira et al., 2009; Heleno et al., 2010; Heleno et al., 
2012b; Pereira et al., 2012); this topic will be detailed in Section 4; 
- antitumour (Wasser and Weis, 1999a; Wasser, 2002; Borchers et al., 2004; 
Lindequist et al., 2005; Zaidman et al., 2005; Poucheret et al., 2006; Doody et al., 2007; 
Moradali et al., 2007; Zhang et al., 2007; Ferreira et al., 2010); this topic will be detailed 
in Section 4;  
- antimicrobial and antiparasitic (Barros et al., 2007; Barros et al., 2008a; Barros et 
al., 2008b; Rao et al., 2009; Alves et al., 2012);  
- immunomodulatory (Chiu et al., 2000, Lull et al., 2005; Moradali et al., 2007; 
Israilides et al., 2008); 
- antiatherogenic (Kaneda and Tokuda, 1966; Bobek and Galbavý, 1999; Yamada et 
al., 2002; Mori et al., 2008);  
- hypocholesterolemic (Kaneda and Tokuda, 1966; Bobek et al., 1991; Bobek et al., 
1994; Bobek et al., 1995; Bobek and Ozdín, 1996; Bobek et al., 1998; Bobek and Galbavý, 
1999) and  
- hypoglycemic (Wasser and Weis, 1999). 
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The bioactivity of Basidiomycetes (Agaricomycetes) mushrooms was confirmed by 
Lucas for the first time back  in 1957 (Lucas, 1957). In this study, a substance from Boletus 
edulis that had a significant growth inhibitory effect against Sarcoma S-180 tumour cells 
was isolated. Carrying out an extensive study in 1966, Gregory and their collaborators 
isolated the active substances from the fruiting bodies of more than 200 Basidiomycetes 
(Agaricomycetes)  mushroom species, and from 7000 culture media produced by applying 
submerge fermentation to the correspondent mushroom types with antitumour activity 
(Gregory, 1966).  
A wide variety of pathological damage related to the ageing process (such as DNA 
damage, carcinogenesis and cellular degeneration) can be caused by reactive oxygen 
species (ROS) produced by sunlight, ultraviolet or ionizing radiation, chemical reactions 
and metabolic processes (Ferreira et al., 2009). Furthermore, there is a vast accumulation 
of studies that implicate oxygen derived free radicals such as superoxide, hydroxyl radicals 
and high energy oxidants such as peroxynitrite as mediators of inflammation, shock and 
ischemia/reperfusion injury. There is also growing evidence to show that production of 
ROS at the site of inflammation can contribute to tissue damage. Therefore, interventions 
against ROS could exert beneficial effects on inflammation and shock (Halliwell and 
Gutteridge, 1984). In this context, several mushroom species have been studied for their 
antioxidant activities (Ferreira et al., 2009). This will be further detailed in section 4. 
Many species of mushrooms have been found to be highly potent immune system 
enhancers, potentiating human and other animals immunity against cancer (Borchers et 
al., 2004; Brzin et al., 2000; Wasser and Weis, 1999; Ikekawa, 2001; Poucheret et al., 
2006; Moradali et al., 2007). At least 30 mushroom species have yielded compounds with 
pronounced anticancer potential in xenographs of human tumours in mice, but only a 
small number have been taken to the next step, which is the objective clinical assessment 
for anticancer potential in humans (Ferreira et al., 2010). This will be further detailed in 
section 4. 
1.3 FUNGI BIODIVERSITY IN NORTHEAST OF PORTUGAL 
Recent estimates indicate the existence of approximately 1.5 million species of 
fungi worldwide, of which about 55,000 are mushrooms (macrofungi). This enormous 
diversity of the Fungi makes this kingdom the major group of organisms known. 
Mushrooms can be found in virtually all natural habitats and semi-natural habitats, 
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from rainforests to the frozen wastes of Antarctica. Yet it is in forest ecosystems that 
they find their ideal ecological conditions (Figure 2).  
 
 
 
 
 
 
 
 
The northeast of Portugal, due to its climatic conditions and flora diversity, is one 
of the European regions with a high diversity of wild edible mushrooms, some of them 
with great gastronomic relevance. Within the local edible species, Lactarius deliciosus, 
Boletus edulis, Hydnum rufescens and Cantharellus cibarius are the most important 
because of their high consumption by the rural population and their economic value in 
the markets of France and Spain (Martins et al., 2002; Baptista et al., 2003).  
Several wild mushrooms species collected in this region have already been 
identified and further characterized (Table 1). 
Table 1. List of the wild mushroom species from Northeast of Portugal already studied. 
Mushroom species 
Ecology/ 
Edibility 
Aspects studied 
Ref. Nutritional 
value 
Chemical 
characterizationa 
Antioxidant 
activity 
Antimicrobial 
activity 
Agaricus arvensis S/E x x x X Barros et 
al., 2007; 
Alves et 
al., 2012 
Agaricus bisporus S/E x x x x Barros et 
al., 
2008c; 
Alves et 
al., 2012 
Agaricus 
campestris 
S/E x x x  Pereira et 
al., 2012 
Figure 2. Northeast of Portugal [adapted from (Gaspar, 2003)]. 
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Mushroom species 
Ecology/ 
Edibility 
Aspects studied 
Ref. Nutritional 
value 
Chemical 
characterizationa 
Antioxidant 
activity 
Antimicrobial 
activity 
Agaricus 
comtulus 
S/E x x x  Pereira et 
al., 2012 
Agaricus lutosus S/E x x x  Pereira et 
al., 2012 
Agaricus 
silvaticus 
S/E x x x x Barros et 
al., 
2008c  
Agaricus silvicola   S/E x x x x Barros et 
al., 
2008c 
Amanita caesarea M/C  x x  Reis et 
al., 2011a 
Amanita 
muscaria 
M/NE  x x  Reis et 
al., 2011a 
Amanita 
pantherina 
M/NE  x x  Reis et 
al., 2011a 
Amanita 
porphyria 
M/NE  x x  Reis et 
al. 2011b 
Amanita 
umbrinolutea 
M/E x x x  Pereira et 
al., 2012 
Boletus aereus  M/C x x x  Heleno et 
al., 2011 
Boletus 
armeniacus 
M/E x x x  Pereira et 
al., 2012 
Boletus 
citrinoporus 
M/NE  x x  Reis et 
al. 2011b 
Boletus edulis M/E x x x  Heleno et 
al., 2011 
Boletus 
erythropus 
M/E x x x  Grangeia 
et al., 
2011 
Boletus fragrans M/E x x x  Grangeia 
et al., 
2011 
Boletus impolitus M/E x x x  Pereira et 
al., 2012 
Boletus purpureus M/NE x x x  Heleno et 
al., 2011 
Boletus 
reticulates 
M/E x x x  Heleno et 
al., 2011 
Boletus 
rhodoxanthus   
M/NE x x x  Heleno et 
al., 2011 
Boletus satanas M/NE  
 
x x  Heleno et 
al., 2011 
Bovista aestivalis S/E x x x  Pereira et 
al., 2012 
Bovista 
nigrescens 
S/E x x x  Pereira et 
al., 2012 
Calvatia 
utriformis 
S/E x x x  Grangeia 
et al., 
2011 
Cantharellus 
cibarius 
M/E x x x x Barros et 
al., 
2008a; 
Alves et 
al., 2012 
Chlorophyllum 
rhacodes 
S/C x x x  Pereira et 
al., 2012 
Chroogomphus 
fulmineus 
  x x  Reis et 
al., 2011a 
Clavariadelphus  x x x  Pereira et 
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Mushroom species 
Ecology/ 
Edibility 
Aspects studied 
Ref. Nutritional 
value 
Chemical 
characterizationa 
Antioxidant 
activity 
Antimicrobial 
activity 
pistillaris al., 2012 
Clavariadelphus 
truncates 
 x x x  Pereira et 
al., 2012 
Clitocybe costata  x x x  Pereira et 
al., 2012 
Clitocybe gibba  x x x  Pereira et 
al., 2012 
Clitopilus 
prunulus 
S/E x x x  Grangeia 
et al., 
2011 
Collybia fusipes S/NE  x x  Reis et 
al. 2011b 
Coprinopsis 
atramentaria 
S/E  x x  Heleno et 
al., 
2012b 
Cortinarius 
anomalus 
  x x  Reis et 
al., 2011a 
Cortinarius 
collinitus 
  x x  Reis et 
al., 2011a 
Cortinarius 
glaucopus 
 x x x  Heleno et 
al., 2009 
Cortinarius 
violaceus 
  x x  Reis et 
al., 2011a 
Fistulina hepatica P/E  x x x Heleno et 
al., 
2009; 
Alves et 
al., 2012 
Flammulina 
velutipes  
 x x x  Pereira et 
al., 2012 
Fomitopsis 
pinicola  
S/NE  x x  Reis et 
al., 2011b 
Ganoderma 
lucidum 
P or S/E  x x  Heleno et 
al., 
2012a 
Hebeloma 
sinapizans 
M/NE  x x  Reis et 
al., 2011b 
Hygrophoropsis 
aurantiaca 
 x x   Heleno et 
al., 2009 
Hygrophorus 
chrysodon 
 x x x  Pereira et 
al., 2012 
Hygrophorus 
pustulatus 
M/E x x x  Grangeia 
et al., 
2011 
Hypholoma 
capnoides 
 x x   Heleno et 
al., 2009 
Inocybe splendens  S/NE  x x  Reis et 
al., 2011b 
Laccaria laccata  x x   Heleno et 
al., 2009 
Lactarius 
bertillonii 
M/NE  x x  Heleno et 
al., 
2012b 
Lactarius 
deliciosus 
M/E x x x x Barros et 
al., 2007; 
Alves et 
al., 2012 
Lactarius 
hepaticus  
M/NE  x x  Reis et 
al., 2011b 
Lactarius quietus  x x   Reis et 
al., 2011a 
Lactarius M/E x x  x Heleno et 
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Mushroom species 
Ecology/ 
Edibility 
Aspects studied 
Ref. Nutritional 
value 
Chemical 
characterizationa 
Antioxidant 
activity 
Antimicrobial 
activity 
salmonicolor  al., 
2009; 
Alves et 
al., 2012 
Lactarius 
vellereus  
M/NE  x x  Heleno et 
al., 
2012b 
Lactarius volemus  x x   Reis et 
al., 2011a 
Lentinus tigrinus S/NE  x x  Reis et 
al., 2011b 
Lepista inversa  x x   Heleno et 
al., 2009 
Lepista nuda S/E x x x x Barros et 
al., 
2008a; 
Alves et 
al., 2012 
Leucoagaricus 
leucothites 
 x x x  Pereira et 
al., 2012 
Leucopaxillus 
giganteus 
S/E x x x x Barros et 
al., 2007; 
Alves et 
al., 2012 
Lycoperdon 
echinatum  
S/E x x x  Grangeia 
et al., 
2011 
Lycoperdon molle  x x x x Barros et 
al., 
2008a 
Lycoperdon 
perlatum 
 x x x x Barros et 
al., 
2008a 
Lycoperdon 
umbrinum 
 x x x  Pereira et 
al., 2012 
Lyophyllum 
decastes 
S/E x x x  Grangeia 
et al., 
2011 
Macrolepiota 
excoriata 
S/E x x x  Grangeia 
et al., 
2011 
Mycena rosea S/E    x Alves et 
al., 2012 
Paxillus involutus M/NE  x x  Reis et 
al., 2011c 
Piptoporus 
betulinus  
P/NE  x x  Reis et 
al., 2011b 
Pisolithus arhizus M/E  x x  Reis et 
al., 2011c 
Pluteus murinus  S/NE  x x  Reis et 
al., 2011b 
Ramaria aurea M/E x x x  Pereira et 
al., 2012 
Ramaria botrytis  M/E x x x x Barros et 
al., 
2008a; 
Alves et 
al., 2012 
Rhodotus 
palmatus 
S/UK  x x  Heleno et 
al., 
2012b 
Russula 
cyanoxantha 
M/E x x x  Grangeia 
et al., 
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Mushroom species 
Ecology/ 
Edibility 
Aspects studied 
Ref. Nutritional 
value 
Chemical 
characterizationa 
Antioxidant 
activity 
Antimicrobial 
activity 
2011 
Russula delica M/E x x  x Heleno et 
al., 
2009; 
Alves et 
al., 2012 
Russula emetica  M/NE  x x  Reis et 
al., 2011b 
Russula olivacea  M/E x x x  Grangeia 
et al., 
2011 
Russula sardonia M/NE  x x  Reis et 
al., 2011a 
 Sarcodon 
imbricatus 
M/E x x x x Barros et 
al., 2007; 
Alves et 
al., 2012 
Suillus luteus M/E  x x  Reis et 
al., 2011a 
Suillus 
mediterraneensis 
M/E  x x  Heleno et 
al., 2009 
Suillus variegatus M/E x x x  Pereira et 
al., 2012 
Tricholoma 
imbricatum  
S/E x x   Heleno et 
al., 2009 
Tricholoma 
portentosum  
M/E x x x x Barros et 
al., 2007; 
Alves et 
al., 2012 
Tricholoma ustale  M/NE  x x  Reis et 
al., 2011a 
Xerocomus 
chrysenteron 
M/E  x x  Heleno et 
al., 
2012b 
aCompounds identified: phenolic compounds, tocopherols, ascorbic acid, β-carotene. 
M - Mycorrhizal; S – Saprotrophic; P – Parasitic; E – Edible; NE – Not edible; C – Choice; UK – Unknown. 
The popularity of mushrooms in the northeast of Portugal and their increasing 
exportation to countries like Spain, France and Italy, justify the further study of these wild 
species. Thus, knowledge of the properties of these species of wild mushrooms should be 
well documented and disseminated, in order to allow better management of their potential 
use and the conservation of their habitats (Ferreira, 2011). 
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2. ANTIOXIDANT ACTIVITY 
All aerobic organisms require molecular oxygen as electron acceptor for the 
production of energy. 
In the metabolism of aerobic biological systems a continuous production of  (ROS) 
and reactive nitrogen species (RNS) occurs. Other possible sources of ROS are air 
pollutants, tobacco or smoke, UV radiation and a diet high in polyunsaturated fatty acids 
(Goetz and Luch, 2008). When this balance tends to produce free radicals, the body is 
under oxidative stress (Figure 3). Free radicals in excess can oxidize and damage cellular 
lipids, proteins and DNA, inhibiting their normal function and leading to various diseases 
such as cancer (Valko et al., 2007; Ferreira et al., 2009). The majority of the targets of 
oxidative stress at the cellular level are the cell membrane (causing inactivation of 
enzymes and changes in transmembrane transport), the cytoplasm and its components 
(proteins and lipids) and, mostly, the genetic material (causing mutagenesis, 
carcinogenesis and aging). 
 
Figure 3. Schematic representation of the balance between production of free radicals and antioxidant 
defences. 
2.1 OXIDATIVE STRESS 
The expression of free radicals produced from natural metabolism of aerobic cells is 
mostly ROS. Once produced, most of the free radicals are neutralized by cellular 
antioxidant defences (enzymes and non-enzymatic molecules) (Figure 4). Beneficial 
effects of ROS occur at low or moderate concentrations and involve cellular physiological 
roles of signalization and regulation (Freidovich, 1999; Fang et al., 2002). 
ROS production
Antioxidant  defences 
(endogenous and exogenous)
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Figure 4. Overview of the main reactions involving reactive Oxygen species (ROS) / reactive Nitrogen species 
(RNS), and major endogenous enzymatic and non-enzymatic antioxidant defences in the cell. 
Representative endogenous enzymatic and non-enzymatic antioxidant defences in the cell [adapted from 
Ferreira et al. 2009)]. Representative endogenous sources (traced rectangles). Main antioxidant defences 
(shaded rectangles) and the enzymes involved (in italic). 
As can be seen in Figure 4, the most representative endogenous sources of ROS/RNS 
include: Mitochondrial ETS (Electron transport system), NADPH oxidases, Xanthine 
oxidase for ROS and NO synthases for RNS.  The addition of one electron to molecular 
Oxygen forms the superoxide anion (O2 •-), which is considered the “primary” ROS. 
Superoxide anion is mostly produced in mitochondria, due to a small but continuous 
“leak” of the electrons in the mitochondrial electron transport system (ETS). These 
electrons generate superoxide anion instead of reducing oxygen to water. Superoxide 
anion can also be produced by different endogenous enzymatic systems present in the cell 
like NADPH oxidases and xanthine oxidase.  O2•- is not a very active radical, it can interact 
with other molecules generating what are considered as “secondary” ROS, such as 
hydrogen peroxide (H2O2) and hydroxyl radical (OH•). Hydroxyl radical has a very short 
life time but is considered to be the most toxic among all ROS. Hydroxyl radical is the 
neutral form of the hydroxide ion and it is formed by an electron transfer from transition 
metals to H2O2, and interacts with biomolecules immediately after generation (Ferreira et 
al., 2009). 
Maintenance of the equilibrium between free radicals production and antioxidant 
defences is an essential condition for the normal function of organisms (Valko et al. 
2007).  
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Oxidative stress is caused by an imbalance between the production of reactive oxygen 
and a biological system's ability to readily detoxify the reactive intermediates or easily 
repair the resulting damage (Machlin and Bendich, 1987). 
Disturbances in this normal redox state can cause toxic effects through the production 
of peroxides and free radicals that damage all components of the cell, including proteins, 
lipids and DNA, leading to their modification and inhibiting their normal function (Fu et 
al., 1998; Ridnour et al., 2005; Valko et al. 2007). 
In humans, oxidative stress might have natural causes such as extreme exercise or 
inflammation processes, or non-natural causes such as the presence of xenobiotics in the 
organism  or situations related to several diseases, such as several kinds of cancer (Valko 
et al. 2006), diabetes (Valko et al. 2007), cirrhoses (Wei et al., 2004), cardiovascular 
diseases (atherosclerosis, heart failure, myocardial infarction) (Shah and Channon, 2004), 
neurological disorders (Parkinson's and Alzheimer's diseases) (Moreira, et al., 2008), 
fragile X syndrome and chronic fatigue syndrome. Nevertheless, short-term oxidative 
stress may also be important in the prevention of aging by induction of a process named 
mitohormesis (Barja, 2004). 
Considering that 70% of the chronical diseases and related costs can be prevented, the 
knowledge about ROS and about the control of their overproduction is crucial (Ferreira et 
al., 2009). This control can be achieved by the maintenance of good levels of antioxidants 
and free radicals scavengers, increasing the quality of diet (higher consumption of 
vegetables, leguminous and fruits) or avoiding behaviours that lead to a higher production 
of ROS, such as tobacco, excessive exposure to environmental polluents and xenobiotics 
(Lachance et al., 2001).  
Nevertheless, ROS can be beneficial, as they are used by the immune system as a way 
to attack and kill pathogens. These species are also used in cell signaling (Barja, 2004). 
2.2 ENDOGENOUS ANTIOXIDANT DEFENCES  
As mentioned previously, antioxidant defence systems protect cellular homeostasis 
from oxidative disruption by reactive molecules generated through the reduction of 
molecular oxygen. The efficient functionality of these mechanisms requires the concerted 
action of the individual systems. These defence systems also have to be in concert with the 
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components responsible for the repair processes of oxidatively damaged molecules in 
order to maintain the cell integrity. 
The endogenous antioxidant defences may be enzymatic or nonenzymatic. The 
enzymatic antioxidant defences are numerous and are spread throughout the body. 
Examples of these defences are superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase (GPx), glutathione reductase (Gred). Among the non-enzymatic antioxidant 
defences are compounds such as glutathione (GSH), α-tocopherol (Vit. E) and ascorbic 
acid (Vit. C) (Figure 3; Ferreira et al., 2009). 
SOD converts O2•- into H2O2, which is then detoxified to water either by CAT in the 
peroxysomes or by GPx in the mitochondria, cytosol or nucleus. GPx are a group of 
selenoenzymes that require Selenium on their biosynthesis. Another important enzyme is 
Gred, which regenerates GSH that is used as a hydrogen donor by GPx. GPx can also 
transform hydroperoxide lipids into alcohols (LOH). Glutathione (GSH) is a low molecular 
weight tripeptide composed of glutamate, cysteine, and glycine being the main 
intracellular redox buffer. The capacity of GSH to regenerate the most important 
antioxidant molecules is linked with the redox state of the glutathione 
disulphide/glutathione (GSSG/GSH) couple. GSH effectively scavenges ROS (HO•, H2O2, 
LOO• and ONOO-) either directly or indirectly as a cofactor of several detoxifying enzymes, 
e.g. GPx, GST, among others. In the neutralization process of ROS, GSH is oxidized to 
glutathione disulphide (GS-SG), which can be further reduced to two GSH by the enzyme 
Gred. GSH is also able to regenerate other antioxidant molecules such as vitamins C and 
E. GSH can also react with a variety of electrophilic xenobiotics in reactions catalysed by 
glutathione-Stransferases (GST) generating products with higher solubility and thus easier 
to eliminate. GSH can also neutralize NO•, resulting in the formation of S-
nitrosoglutathione (GSNO). Vitamin E is a liposoluble vitamin present in the membranes 
thus playing an important role in the prevention of lipid peroxidation. Among the eight 
forms of vitamin E, β-tocopherol is the most active form in humans. ROS (hydroxyl and 
peroxyl radicals, etc.) react with vitamin E, generating a poorly reactive phenolic radical 
(vit. E•). Vitamin C then reacts with vit. E• producing vitamin C radical (vit. C•) and 
regenerating vitamin E. Both radicals (vit. E• and vit. C•) are poorly reactive species 
because of its unpaired electron. 
In addition to the endogenous defences, there is a range of natural or synthetic 
molecules with antioxidant properties that may be an exogenous system of defence. A 
multitude of natural antioxidants have already been isolated from different kinds of plant 
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materials such as oilseeds, cereal crops, vegetables, fruits, leaves, roots, spices, and herbs 
(Ferreira et al., 2009). 
Some natural products with antioxidant activity may be useful to aid the system 
endogenous defences, being used as nutraceuticals. 
2.3 EXOGENOUS ANTIOXIDANT DEFENCES: THE CASE STUDY OF 
PHENOLIC ACIDS 
Among the biologically active substances present in mushrooms, phenolic compounds 
have attracted much attention due to their very good properties as antioxidant, anti-
inflammatory or antitumour agents, among others (Puttaraju et al., 2006).  
Phenolic compounds are aromatic hydroxylated compounds, possessing one or more 
aromatic rings with one or more hydroxyl groups. They include a large number of 
subclasses, such as flavonoids, phenolic acids, including hydroxybenzoic acids and 
hydroxycinnamic acids, stilbenes, lignans, tannins, and oxidised polyphenols, displaying 
an enormous diversity of structures (D’Archivio et al., 2010; Cote et al., 2010). 
Phenolic acids within mushrooms (Figure 5 and 6) are strong antioxidants and may 
alleviate oxidative stress by quenching or neutralising reactive species, thereby reducing 
cellular damage or death (Andreasen et al., 2001; Zhou and Yu, 2004). Besides acting as 
antioxidants, these compounds can be beneficial to health by chelating metal ions (Liyana-
Pathirana and Shahidi, 2006), stimulating antioxidative (Moore et al., 2006) and 
detoxifying (Yoshioka et al., 1995) enzymes, and inhibiting transcription factors that 
initiate and promote tumour cell growth (Yoshioka et al., 1995; Natarajan et al., 1996).   
 
 
 
 
 
 
 
Benzoic acid derivatives Substitution 
X R1 R2 R3 R4 
p-Hydroxybenzoic COOH H H OH H 
Protocatechuic COOH H H OH OH 
Gallic COOH H OH OH OH 
Gentisic  COOH OH H H OH 
Homogentisic  CH2COOH OH H H OH 
Vanillic COOH H OCH3 OH H 
5-Sulphosalicylic COOH OH H H HSO3 
Syringic COOH H OCH3 OH OCH3 
Veratric  COOH H OCH3 OCH3 H 
Vanillin  CHO* H OCH3 OH H 
Figure 5. Chemical structure of the benzoic acid derivatives found in mushrooms [adapted from (Ferreira et 
al., 2009.)]. 
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Figure 6. Chemical structure of the cinnamic acid derivatives found in mushrooms [adapted from (Ferreira 
et al., 2009)]. 
Phenolic compounds can be classified as free radical inhibitors (chain breakers), 
peroxide decomposers, metal inactivators or oxygen scavengers. Biological antioxidant 
capacity can be measured by controlling the inhibition of induced lipid oxidation 
(Tsukihara et al., 2008). These methods induce the auto-oxidation of linoleic acid or low-
density lipoproteins (LDL) by Cu(II) or an azo initiator and control the formation of 
conjugated diene peroxides. 
Free radicals, generated by the initiator, react with oxygen species yielding peroxide 
radicals which attack the lipids to form the conjugated diene peroxides. Therefore, the 
scavenging of free radicals or peroxide radicals by an antioxidant agent may avoid the lipid 
oxidation in biological systems (Palacios et al., 2011).  Gallic acid (3,4,5-tri-
hydroxybenzoic acid) has a greater antioxidant activity than protocatechuich acid (3,4-
dihydroxybenzoic acid), apparently due to the presence of more hydroxyl groups (Cuvelier 
et al., 1992; Palacios et al., 2011). 
Substitutions with methoxyl groups (electron donors) in a position ortho to the 
hydroxyl group increases the antioxidant activity by stabilizing the phenoxyl radical, 
sinapic acid> ferulic acid> p-coumaric acid and syringic acid> vanillic acid> p-
hydroxybenzoic acid. However, the antioxidant activity of methoxyl groups is always 
inferior to the presence of hydroxyl groups: e.g. ferulic acid <caffeic acid and vanillic acid 
<protocatechuich acid (Cuvelier et al., 1992). 
The esterification with quinic acid decreases the antioxidant activity, chlorogenic acid 
<caffeic acid. The allyl group present in cinnamic acid (CH = CHCOOH) derivatives 
appears to increase the antioxidant activity compared to benzoic acid (COOH) derivatives: 
caffeic acid> protocatechuich acid, sinapic acid> syringic acid, ferulic acid> vanillic acid 
Cinnamic acid 
derivatives 
Substitution 
X R1 R2 R3 R4 
p-Coumaric H H H OH H 
o-Coumaric H OH H H H 
Caffeic H H OH OH H 
Ferulic H H CH3 O OH H 
Sinapic CH3O H CH3O OH CH3O 
3-O-caffeoylquinic  * H OH OH H 
4-O-caffeoylquinic * H OH OH H 
5-O-caffeoylquinic * H OH OH H 
* The carboxylic group is esterified with quinic acid 
CHR3
R4
R2
CH C
O
O
X
R1
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and p-coumaric acid> p-hydroxybenzoic acid. The double bond C = C appears to 
participate in the stabilization of the phenoxyl radical (Cuvelier et al., 1992). 
The individual profile of phenolic compounds in wild mushrooms has been  obtained 
by high-performance liquid chromatography coupled to photodiode array 
detector/electrospray ionization mass spectrometry (HPLC-DAD/ESI-MS) (Barros et al., 
2009), with UV detector (HPLC-UV) or Gas chromatography coupled to mass 
spectrometry (GC-MS) (Ferreira et al., 2009). 
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3. CANCER CELLS GROWTH 
Cancer has become a major public health problem worldwide with an estimated 
prevalence of about 3%, increasing to 15% in individuals aged over 65 years. Cancer is the 
leading cause of death in economically developed countries and the second leading cause 
of death in developing countries. The burden of cancer is increasing in economically 
developing countries as a result of population aging and growth as well as, increasingly, an 
adoption of cancer-associated lifestyle choices including smoking, physical inactivity, and 
‘‘westernized’’ diets (Jemal et al., 2011). Moreover, cancer related deaths are projected to 
increase to over 11 million in 2030 (World Health Organization, 2010).  
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have 
occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the 
economically developing world. Breast cancer in females and lung cancer in males are the 
most frequently diagnosed cancers and the leading cause of cancer death for each sex in 
both economically developed and developing countries, except that lung cancer is 
preceded by prostate cancer as the most frequent cancer among males in economically 
developed countries (Jemal et al., 2011). 
Many years of research have revealed that cancer results from genetic alterations in 
cancer cells which confer advantages to those cells, such as capacity of unlimited division 
and evasion of cell death. Hanahan and Weinberg (2012), claim that the most 
fundamental trait of cancer cells involves their ability to sustain chronic proliferation.  
The main approaches to cancer treatment are surgical excision, radiotherapy and 
chemotherapy. The use of anticancer drugs, as part of a treatment strategy to cancer, has 
greatly improved the overall prognosis of cancer patients (Maser and DePinho, 2002; 
Finkel et al., 2007). Therefore, efforts to discover new medicines for treating cancer and to 
predict their clinical activity are essential (Sharma et al., 2010).   
In normal cells, growth, division and differentiation are highly regulated processes. 
Some signaling molecules—called growth factors—promote cell division. Other signaling 
molecules cause cells to stop growing. Many signaling molecules, including growth factors 
and growth inhibitors, bind to receptors on the surface of the cell. In many cases, these 
receptors must interact with one another, or dimerize, before they can become fully 
activated (Walensky, 2006). 
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Unlike normal cells, cancer cells display uncontrolled growth control, so they can 
ignore signals to stop growing. Some cancer cells can make their own growth factors. 
These growth factors travel to the outside of the cell, where they interact with and activate 
the cancer cell's growth factor receptors. Some cancer cells make more growth factor 
receptors than normal cells—this is called overexpression. Cancer cells with overexpressed 
growth factor receptors may be stimulated to grow when growth factors are present at 
levels that would be too low to stimulate growth of normal cells. This is because by having 
more receptors available increases the chances that a growth factor will find its receptor. 
Other cancer cells may have mutations in the genes that code for growth factor receptors. 
Some of these mutations result in the formation of dysfunctional receptors, which remain 
in the "ON" position for growth even when no growth factor is present (Barinaga, 1996; 
Walensky, 2006).  
Because cancer cells display uncontrolled cell growth, most anticancer therapy is 
aimed at increasing levels of cell death and reducing cellular proliferation (Schreader and 
Nambu, 2004; Hague and Verkhratsky, 2009). 
3.1 SCREENING ASSAYS OF INHIBITION OF CELL GROWTH   
Practical endpoints for microplate cytotoxicity assays did not exist until the time when 
the US National Cancer Institute (NCI) model was conceived, in the late 1980s 
(Shoemaker, 2006). Indeed, the tritiated thymidine incorporation assay that was widely 
used until then for growth-inhibition studies was prohibitively expensive for large-scale 
screening.   
One of the presently existing assays for evaluation of cell growth inhibitory activity is 
the Alamar blue assay. Alamar blue is a sensitive oxidation–reduction indicator that 
fluoresces and changes color upon reduction by living cells. The reduction of Alamar blue 
is believed to be mediated by mitochondrial enzymes (O’Brien et al., 2000). However, 
Gonzalez and Tarloff (2001) suggest that cytosolic and microsomal enzymes contribute to 
the reduction of Alamar blue.  
The MTT assay is another presently well-documented cell metabolic assay and has 
been modified by several investigators since it was first developed by Mosmann in 1983 
(Hamid et al., 2004). This assay is based on the cleavage of the yellow tetrazolium salt, 
MTT, by mitochondrial enzymes, to form a soluble blue formazan product. The amount of 
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formazan produced is directly proportional to the number of living cells present during 
MTT exposure (Sylvester, 2011). 
Since the MTT assay is rapid, convenient, and economical, it has become a very 
popular technique for quantification of metabolically active cells in culture (Vistica, 1991; 
Sylvester, 2011). However, various parameters have been identified that may affect cellular 
metabolism, which significantly modify MTT-specific activity and can result in calculated 
false high or low cell growth results (Sylvester, 2011). 
Therefore, it is essential to establish the assay parameters with the proper controls for 
each cell line and/or drug treatment, in order to optimize the assay conditions and 
minimize confounding effects. These parameters should include determining appropriate 
cell densities, culture medium, optimal concentrations and exposure times for MTT, fresh 
culture medium at the time of assay initiation to avoid nutrient depletion, and controlling 
the drug treatment effects that may influence cellular metabolism. A limitation of the MTT 
assay is that the formazan product is insoluble in aqueous medium, so a step is required to 
solubilize the formazan before reading the optical density. To circumvent this, a new 
tetrazolium assay was developed based on a reagent designated XTT (Vistica, 1991). 
The XTT cell growth assay was first described by Scudiero (1988), as an effective 
method to measure cell growth and drug sensitivity in tumour cell lines. XTT is a 
colourless or slightly yellow compound that when reduced becomes brightly orange. This 
color change is accomplished by breaking apart the positively-charged quaternary 
tetrazole ring (Berridge et al., 2005). The formazan product of XTT reduction is soluble 
and can be used in real-time assays.  XTT is thought to be excluded from entering cells by 
its net negative charge (Berridge et al., 2005). Considerable evidence suggests that XTT 
dye reduction occurs at the cell surface facilitated by trans-plasma membrane electron 
transport. Mitochondrial oxidoreductases are thought to contribute substantially to the 
XTT response, with their reductants being transferred to the plasma membrane. It has 
been proposed that XTT assays actually measure the pyridine nucleotide redox status of 
cells (Marshall et al., 1999; Berridge et al., 2005). The XTT assay served as an efficient 
bioassay tool for the isolation of natural products with anticancer potential and provided 
the basis for the NCI anti-HIV drug screen (Sausville and Shoemaker, 2001).  
Alternative approaches were investigated, including a methylene blue assay, and a 
method that used sulphorhodamine B (SRB) was finally selected by NCI for use in the 
screening of tumour cell growth.  
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The SRB assay, based on the measurement of cellular protein content, is used for cell 
density determination (Keepers et al., 1991). This method has been optimized for the 
toxicity screening of compounds in cell lines, in a 96-well plate. The results are linear over 
a 20-fold range of cell numbers and the sensitivity is comparable to those of fluorometric 
methods. This method not only allows a large number of samples to be tested within a few 
days, but also only requires simple equipment and inexpensive reagents. The assay also 
has the advantage of allowing some degree of differentiation between cell kill from cell 
growth inhibition (Skehan et al., 1990). 
The SRB assay is therefore an efficient and highly cost-effective method for screening 
compounds or natural products (Skehan et al., 1990; Vichai and Kirtikara; 2006).  This 
assay proved to be robust and feasible for medium-scale screening (Monks et al., 1997).  
The application of the SRB assay to the pilot-scale screening of test sets of 
compounds, including approved anticancer drugs, led to the recognition of the profiles of 
cell line sensitivity and resistance, reflecting mechanisms of growth inhibition and cell 
killing (Shoemaker, 2006).  
3.2 CELL PROLIFERATION AND CELL DEATH  
Cell proliferation 
The core of cellular proliferation is the cell cycle division. This process includes a 
series of events occurring in an ordered sequence, which result in genome duplication and 
segregation to daughter cells following division (Figure 7). Cell cycle is comprised of two 
active phases: the S phase, in which DNA synthesis/chromosome replication occurs 
(Alberts et al., 2002), and the M phase (mitosis), in which separation of the chromosomes 
followed by cell division (cytokinesis) occurs. These processes are separated by two gaps 
(G1 and G2). 
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Figure 7. Simple representations of cell cycle and some of its regulators [adapted from (Wang et al., 2009)]. 
The purple circle represents phases G1, S, G2, and M of the cell cycle. The cyclin/cyclin-dependent kinases 
(CDK) complexes present on each phase are represented surrunded by a circle.  
During the G2 phase biosynthesis occurs, mainly the production of microtubules, 
which are required for the process of mitosis. The relatively brief M phase consists of 
nuclear division (karyokinesis), followed immediately by cytokinesis. Finally, there is a 
fifth state, G0 (also known as quiescence) into which the cell may reversibly exit from G1, 
if it is deprived of the appropriate growth-promoting signals (Morgan, 2007). 
Progression through the cell-division cycle is driven by activation and inactivation of 
cyclin-dependent kinases (CDKs), which trigger the transition to the subsequent phases of 
the cycle. CDKs are small serine/threonine protein kinases that require association with a 
cyclin subunit for their activation (Besson et al., 2008).  
Many levels of regulation exist to impose tight control over cell-cycle progression 
(Schwartz and Shah, 2005). Such regulation involves controlled expression and 
destruction of cyclins, activating and inhibitory phosphorylation and dephosphorylation of 
the CDKs, and expression or destruction of inhibitory proteins that associate with CDKs, 
or CDK/cyclin complexes (Figure 7).  Two families of genes, the cip/kip family (such as 
p21 or p27) and the INK4a/ARF (inhibitor of kinase 4/alternative reading frame; such as 
p16) prevent the progression of the cell cycle, and are therefore accepted as being tumour 
suppressors (Dynlacht, 1997; Fung and Poon, 2005; Morgan, 2007). 
The regulation of cell cycle ensures quality in cellular DNA replication and division. 
Any deregulation in this mechanism will lead to alterations in cell cycle progression or in 
the replication of DNA that may be mutated or damaged, or even in uncontrolled 
proliferation, thus contributing to tumour development (Paulovich et al., 1997). 
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Several anticancer drugs bind directly to DNA (for example, intercalating agents), 
interfere with DNA synthesis (for example, antimetabolites) or with microtubule 
polymerization/depolymerisation (vinka alkaloids and taxol, respectively), thus 
interfering with the cell division and blocking cell growth (De Falco and De Luca, 2010). 
Cell death 
Programmed cell death is a central mechanism controlling multicellular development, 
and is involved in a variety of biological events. These include morphogenesis, 
maintenance of tissue homeostasis or elimination of harmful cells. Programmed cell death 
leads to deletion of entire structures, sculpts specific tissues (by ablating fields of cells) 
and regulates the number of neurons in the nervous system (Lodish et al., 2000;  Sun and 
Peng, 2009).  
Cellular interactions regulate cell death in two fundamentally different ways. Most 
cells in multicellular organisms, if not all, require signals to stay alive. In the absence of 
such survival signals, frequently referred to as trophic factors, cells activate a “suicide” 
program. On the other hand, in some developmental contexts, including the immune 
system, specific signals induce a “suicide” program that kills cells. Independently of the 
reason for the cells to commit suicide (lack of survival signals or killing signals from other 
cells), recent studies suggest that the death may be mediated by a common molecular 
pathway.  
As mentioned earlier, cell death is a critical process in development and homeostasis 
of normal organisms, but is also important in certain pathological conditions, including 
cancer. Indeed, alterations in the apoptotic machinery, including alterations in its 
regulators, have been described in several human cancers. Moreover, transformed cells 
usually acquire defects in the apoptotic pathways therefore having a survival advantage 
(Mashima and Tsuruo, 2005). 
For several years it had been believed that the mechanism of cell death induced by 
chemotherapy was confined solely to apoptosis (Meier et al., 2000; Sun and Peng, 2009). 
However, accumulating evidence suggested that tumour cellular response to 
chemotherapy includes other modes of cell death (Okada and Mak, 2004). Indeed, there 
are four described modes of cell death that can be induced by chemotherapy: apoptosis, 
necrosis, mitotic catastrophe and autophagy (Ashkenazi, 2002; Galluzzi et al., 2007). 
Senescence, a form of permanent growth arrest, is not a cell death mechanism but is 
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considered of significant importance as a response of cancer cells to chemotherapy (Ricci 
and Zong, 2006). These five kinds of cellular responses are classified based on 
biochemical and morphological features that are present in the dying cells (Galluzzi et al., 
2007). 
One of the most studied forms of programmed cell death is marked by a well-defined 
sequence of morphological changes, collectively referred to as apoptosis, a Greek word 
that means “dropping off” or “falling off” as in leaves from a tree. Dying cells shrink and 
condense and then fragment, releasing small membrane-bound apoptotic bodies, which 
generally are phagocytosed by other cells (Figure 8). This type of cell death is under the 
control of a strict cellular program. Thus, apoptotic cell death acts as part of a quality 
control and repair mechanism by elimination of unwanted, genetically damaged, or 
senescent cells, and as such is critically important for the development of organisms. 
Highly conserved in both plants and animals, it is also the cell death mechanism best 
characterised at both genetic and biochemical levels (Sun and Peng, 2009). 
 
 
 
 
 
 
Activation of apoptosis signaling following treatment with cytotoxic drugs may 
happen through the activation of the mitochondrial pathway (also named as intrinsic 
pathway) or the death receptors pathway (also named as extrinsic pathway) (Figure 9; 
Debatin, 2004). 
As shown in Figure 9, both pathways will converge in the activation of caspases, 
cysteine proteases that are synthesized as inactive zymogens and are activated by 
proteolytic breakdown (Fulda and Debatin, 2004).  
Mild convolution 
Chromatin compaction and 
segregation 
Condensation of cytoplasm 
Nuclear fragmentation 
Blebbing 
Cell fragmentation 
Phagocytosis 
Figure 8. Schematic drawings illustrating the progression of morphologic changes observed in apoptotic cells 
[adapted from (Kuby, 1997)]. Early in apoptosis, dense chromosome condensation occurs along the nuclear 
periphery. The cell body also shrinks, although most organelles remain intact. Later, both the nucleus and 
cytoplasm fragment, forming apoptotic bodies. These are phagocytosed by surrounding cells. 
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In the extrinsic pathway, triggering of cell surface death receptors of the tumour 
necrosis factor (TNF) receptor superfamily, including CD95 and TNF-related apoptosis-
inducing ligand (TRAIL)-R1/-R2, results in rapid activation of the initiator caspase 8 after 
its recruitment to a trimerized receptor-ligand complex (DISC) through the adaptor 
molecule Fas-associated death domain protein (FADD). In the intrinsic pathway, stress-
induced apoptosis results in perturbation of mitochondria and the ensuing release of 
proteins, such as cytochrome c, from the inter-mitochondrial membrane space. The 
release of cytochrome c from mitochondria is regulated in part by Bcl2 family members 
(Adams and Cory, 2007), which comprises anti-apoptotic (e.g. Bcl2/ Bcl-XL/Mcl1) and 
pro-apoptotic (e.g. Bax, Bak and tBid) members (Marshall et al., 1999). Once released, 
cytochrome c binds to apoptotic protease-activating factor 1 (Apaf1), which results in 
formation of the Apaf1–caspase 9 apoptosome complex and activation of the initiator 
caspase 9. The activated initiator caspases 8 and 9 then activate the effector caspases 3, 6 
and 7, which are responsible for the cleavage of important cellular substrates resulting in 
the classical biochemical and morphological changes (Adams and Cory, 2007). 
A role for p53 in apoptosis is well known and accepted. p53 is considered to be a key 
guardian of the genome. It senses DNA damage and in response induces a transient 
growth arrest, allowing DNA repair or, in the case of extensive damage, promotes 
irreversible growth arrest (senescence) or programmed cell death (apoptosis) (Meek, 
2009; Zuckerman et al., 2009). 
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Figure 9. Apoptosis: the extrinsic and intrinsic pathways to caspase activation [adapted from (Danial and 
Korsmeyer, 2004)]. Two major apoptotic pathways are illustrated: one activated via death receptor 
activation (extrinsic) and the other by stress-inducing stimuli (intrinsic). 
 
 
p53 is regarded as a central player in tumour suppression, as it controls programmed 
cell death (apoptosis) as well as cellular senescence. While apoptosis eliminates cells at 
high risk for oncogenic transformation, senescence acts as a barrier to tumourigenesis by 
imposing irreversible cell cycle arrest. p53 can act directly or indirectly at multiple levels 
of the tumour suppression network by invoking a myriad of mechanisms. p53 induces the 
extrinsic and intrinsic apoptotic pathways at multiple steps to ensure an efficient death 
response.  
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p53 response involves transcriptional activation or repression of target genes, as well 
as some recently identified microRNAs, and transcription-independent functions (Figure 
10). Importantly, p53 loss of function is often found in tumours. Therefore, therapeutic 
strategies aimed at reactivation of p53 in tumours emerge as a promising approach for the 
treatment of some cancer patients (Zuckerman et al., 2009). 
A possible approach for the treatment of cancer may be targeting cell cycle (De Falco and 
De Luca, 2010) and/or apoptosis (Ferreira et al., 2010) pathways. But much remains to be 
done in the pursuit of agents capable of targeting such cellular process (Senderowicz, 
2004). 
 
 
p53 in apoptosis 
Transcrition-dependent activity Transcrition-independent activity 
Direct apoptogenic effects in mitochondria 
Bax Bak Bcl-2 Bcl-xl Mcl-1 
Transactivation  Transrepression 
Bcl-2 family (Bax, Bid, 
Puma, Noxa),  
The apoptotic effector 
machinery (Apaf-1, 
Caspase-8, Caspase-6),  
Cell death receptors (DR5, 
FAS),  
Cell death ligands 
(TNFSF10, TNFS6)  
Bcl-2 
Survivin 
ARC 
Gelactin-3 
Figure 10. Multiple mechanisms involved in p53-mediated apoptosis [adapted from (Zuckerman et al., 2009)]. 
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4. MUSHROOMS WITH PROMISING ANTIOXIDANT AND 
TUMOUR CELL GROWTH INHIBITORY ACTIVITIES 
When considering natural species as sources of compounds with potential medicinal 
properties, including antioxidant and tumour cell growth inhibitory activities, mushrooms 
appear represent important sources of therapeutically useful biologically active agents 
(Mizuno, 1995; Wasser, 1995; Wasser, 2002; Ferreira et al., 2010). 
Wild mushrooms contain different antioxidants such as phenolic compounds, 
tocopherols, ascorbic acid and carotenoids, which could be extracted for the purpose of 
being used as functional ingredients, namely against chronic diseases related to oxidative 
stress (Ferreira et al., 2009). Different wild mushroom species have been reported to have 
antioxidant activity, as described in Table 2. 
Table 2. Studies on Antioxidant Properties of Wild Mushrooms [Adapted from (Ferreira et al., 2009)]. 
Mushroom species Antioxidant Activity Assays Country 
Agaricus arvensis DPPH scavenging activity; 
Hemolysis inhibition. 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition;  
Portugal 
Agaricus bisporus  ABTS+ radical cation scavenging activity; 
Chelating effects on cupric ions; 
Chelating effects on ferrous ions;  
DPPH scavenging activity; 
FAD assay; 
Hemolysis inhibition; 
Hydroxyl radicals scavenging activity; 
Inhibition of lipid peroxidation; 
Linoleic acid assay; 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay; 
Thiocyanate method. 
β-carotene bleaching inhibition;  
China 
Korea 
Portugal 
Serbia 
Spain 
Turkey 
 
Agaricus bitorquis ABTS+ radical cation scavenging activity; 
Chelating effects on cupric ions; 
Chelating effects on ferrous ions; 
DPPH scavenging activity; 
β-carotene bleaching inhibition. 
Turkey 
 
Agaricus blazei  ABTS+ radical cation scavenging activity. 
Chelating effects on ferrous ions; 
Conjugated diene method; 
DCF/AAPH assay; 
DPPH  scavenging activity; 
Hydroxyl radicals scavenging activity;  
Hydroxyl radicals scavenging activity;  
Reducing power;  
β-carotene bleaching inhibition. 
Brazil  
Korea  
Taiwan  
Agaricus brasiliensis Chelating ability on ferrous ions; 
DPPH scavenging activity; 
FAD assay; 
Inhibition of lipid peroxidation. 
Serbia 
Agaricus campestris DPPH scavenging activity; 
Reducing power; 
Portugal 
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Mushroom species Antioxidant Activity Assays Country 
β-carotene bleaching inhibition. 
Agaricus comtulus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
 
Agaricus essettei ABTS+ radical cation scavenging activity; 
Chelating effects on cupric ions; 
Chelating effects on ferrous ions; 
DPPH scavenging activity; 
β-carotene bleaching inhibition. 
Turkey 
 
Agaricus lutosus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
 
Agaricus romagnesii  DPPH scavenging activity; 
Hemolysis inhibition. 
Reducing power;  
TBARS assay; 
β -carotene bleaching inhibition. 
Portugal 
Agaricus silvaticus 
 
DPPH scavenging activity; 
Hemolysis inhibition; 
Reducing power; 
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
 
Agaricus silvicola  
 
DPPH scavenging activity; 
Hemolysis inhibition. 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Agrocybe aegerita ABTS+ radical cation scavenging activity. 
DPPH scavenging activity; 
TBARS assay; 
China 
 
Agrocybe cylindracea  
 
Chelating effects on ferrous ions; 
Conjugated diene method; 
DETBA method; 
DPPH scavenging activity; 
Hydroxyl radicals scavenging activity;  
Linoleic acid assay 
Reducing power.  
Spain 
Taiwan 
 
Amanita caesarea Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Turkey  
 
Amanita rubescens DPPH scavenging activity. Portugal 
Amanita umbrinolutea DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Armillariella mellea  TBARS assay. Taiwan 
Auricularia aurícula TBARS assay; 
Hydroxyl radicals scavenging activity 
India 
 Auricularia polytricha DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Boletus armeniacus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Boletus badius Superoxide anion radical scavenging activity; 
Reducing power;  
DPPH scavenging activity; 
Chelating effects on ferrous ions; 
Thiocyanate method. 
Turkey 
Boletus edulis 
 
Chelating effects on ferrous ions. 
Conjugated diene method; 
India 
Portugal 
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Mushroom species Antioxidant Activity Assays Country 
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity;  
Linoleic acid assay. 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Taiwan 
Spain 
Turkey 
Boletus erythropus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Boletus fragrans   DPPH scavenging activity; 
Reducing power. 
β-carotene bleaching inhibition; 
Portugal  
Boletus impolitus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Bovista aestivalis DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Bovista nigrescens DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Calocybe gambosa Linoleic acid assay. 
 
Spain  
Calvatia utriformis β-carotene bleaching inhibition; 
DPPH scavenging activity; 
Reducing power. 
Portugal  
Cantharellus cibarius 
 
DPPH scavenging activity; 
FRAP assay; 
Ferrous ion-chelating effect; 
Linoleic acid assay. 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Turkey 
India 
Portugal 
Spain  
Cantharellus clavatus DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Cantharellus lutescens  Chelating effects on ferrous ions; 
DETBA method; 
DPPH scavenging activity; 
Hydroxyl radicals scavenging activity; 
Reducing power.  
Spain 
Catathelasma ventricosum DPPH scavenging activity; 
Reducing power; 
Metal chelating activity. 
China 
Chlorophyllum rhacodes DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Clavariadelphus pistillaris DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
 
Clavariadelphus truncatus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Clitocybe alexandri DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Clitocybe costata DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Clitocybe geotropa Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Turkey  
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Mushroom species Antioxidant Activity Assays Country 
Clitocybe gibba DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Clitocybe maxima DPPH scavenging activity; 
Metal chelating activity; 
Reducing power. 
China 
Clitopilus prunulus β-carotene bleaching inhibition; 
DPPH scavenging activity; 
Reducing power. 
Portugal  
 Coriolus versicolor Chelating effects on ferrous ions 
DETBA method;  
DPPH scavenging activity. 
Hydroxyl radicals scavenging activity;  
Reducing power. 
Taiwan 
Cortinarius glaucopus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Cortinarius praestans DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Craterellus cornucopioides DPPH scavenging activity; 
Linoleic acid assay; 
Metal chelating activity; 
Reducing power. 
China 
Spain  
Dictophora indusiata  Chelating effects on ferrous ions 
DETBA method; 
DPPH scavenging activity. 
Hydroxyl radicals scavenging activity;  
Reducing power. 
Taiwan 
Fistulina hepatica DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Flammulina velutipes 
  
Chelating effects on ferrous ions 
DETBA method; 
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity; 
Reducing power;  
β-carotene bleaching inhibition. 
Korea 
Portugal 
Taiwan 
Ganoderma applanatum  Chelating ability on ferrous ions; 
DPPH scavenging activity; 
Ferric reducing antioxidant power assay; 
Hydroxyl radicals scavenging activity. 
Inhibition of lipid peroxidation; 
TBARS assay. 
India 
Serbia 
 
Ganoderma lucidum Chelating ability on ferrous ions; 
DETBA method;  
DPPH scavenging activity. 
Ferric reducing antioxidant power assay; 
Hydroxyl radicals scavenging activity;  
Inhibition of lipid peroxidation; 
Reducing power; 
β-carotene bleaching inhibition. 
Korea 
Portugal 
Serbia 
Taiwan 
 
Ganoderma tsugae DETBA method;  
Reducing power;  
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity;  
Chelating effects on ferrous ions 
Taiwan 
Geastrum arinarius DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Geastrum saccatum  Superoxide anion radical scavenging activity; 
TBARS assay; 
Hydroxyl radicals scavenging activity 
Brazil 
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Mushroom species Antioxidant Activity Assays Country 
Grifola frondosa  Chelating effects on ferrous ions; 
Conjugated diene method. 
DETBA method;  
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity;  
Reducing power;  
SOD activity. 
Korea 
Taiwan 
Helvella crispa Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Hydrogen peroxide scavenging activity. 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay. 
India 
Turkey 
Hericium erinaceus Chelating effects on ferrous ions; 
DETBA method; 
DPPH scavenging activity. 
Hydroxyl radicals scavenging activity; 
Reducing power. 
Taiwan 
Hydnum repandum 
 
Chelating effects on ferrous ions; 
DETBA method; 
DPPH scavenging activity; 
Hydroxyl radicals scavenging activity; 
Linoleic acid assay 
Reducing power; 
TBARS assay. 
β-carotene bleaching inhibition. 
India 
Portugal 
Spain 
Hygrophoropsis aurantiaca DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Hygrophorus agathosmus DPPH scavenging activity. Portugal 
Hygrophorus chrysodon DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Hygrophorus marzuolus Linoleic acid assay. Spain  
Hygrophorus pustulatus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Hypholoma capnoides DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Hypholoma fasciculare  DPPH scavenging activity; 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Hypsizigus marmoreus  Reducing power;  
DPPH scavenging activity; 
Hydroxyl radicals scavenging activity;  
Conjugated diene method; 
Chelating effects on cupric ions. 
Taiwan 
Inonotus obliquus Superoxide anion radical scavenging activity; 
DPPH scavenging activity; 
DCF/AAPH assay. 
Korea 
Laccaria amethystea DPPH scavenging activity; 
Metal chelating activity; 
Reducing power. 
China 
Portugal 
Laccaria laccata DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Lactarius aurantiacus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
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Mushroom species Antioxidant Activity Assays Country 
Lactarius deliciosus  
 
DPPH scavenging activity; 
FRAP assay; 
Ferrous ion-chelating effect; 
Hemolysis inhibition. 
Linoleic acid assay. 
Reducing power;  
TBARS assay. 
β-carotene bleaching inhibition. 
India 
Portugal 
Spain  
Turkey 
Lactarius deterrimus  Reducing power;  
DPPH scavenging activity; 
Chelating effects on ferrous ions; 
β-carotene bleaching inhibition. 
Turkey 
Lactarius piperatus  DPPH scavenging activity; 
Hemolysis inhibition. 
Reducing power;  
Superoxide anion radical scavenging activity; 
β-carotene bleaching inhibition. 
Portugal 
Lactarius salmonicolor DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Lactarius sanguifluus Chelating effects on ferrous ions; 
DPPH scavenging activity. 
Hydrogen peroxide scavenging activity; 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay. 
India 
Turkey 
Laetiporus sulphureus  DPPH scavenging activity;  
β-carotene bleaching inhibition. 
Turkey 
Lentinula edodes  ABTS+ radical cation scavenging activity. 
Chelating ability on ferrous ions; 
DETBA method; 
DPPH scavenging activity; 
Ferric reducing antioxidant power assay; 
Hemolysis inhibition; 
Hydroxyl radicals scavenging activity; 
Inhibition of lipid peroxidation; 
Linoleic acid assay 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Brazil 
China 
Korea 
Serbia 
Spain 
Taiwan 
Lentinus squarrulosus DPPH scavenging activity. 
Reducing power;  
TBARS assay; 
India 
Lentius sajor-caju  TBARS assay; 
Reducing power;  
DPPH scavenging activity. 
India 
Lepista inversa DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Lepista nuda 
 
Chelating effects on ferrous ions; 
DETBA method; 
DPPH scavenging activity. 
Hydroxyl radicals scavenging activity; 
Linoleic acid assay 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay; 
Thiocyanate method. 
β -carotene bleaching inhibition. 
Portugal 
Spain 
Turkey 
Lepista sordida DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Leucoagaricus leucothite DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
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Mushroom species Antioxidant Activity Assays Country 
Leucoagaricus pudicus Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Turkey  
Leucopaxillus giganteus   DPPH scavenging activity; 
Hemolysis inhibition. 
Hemolysis inhibition; 
Reducing power;  
β-carotene bleaching inhibition. 
Portugal 
 
Lycoperdon echinatum DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Lycoperdon molle  DPPH scavenging activity; 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Lycoperdon perlatum  DPPH scavenging activity; 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Lycoperdon umbrinum DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Lyophyllum decastes DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Macrolepiota excoriata DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Macrolepiota mastoidea DPPH scavenging activity; 
Hemolysis inhibition; 
Reducing power;  
TBARS assay; 
β -carotene bleaching inhibition. 
Portugal 
Macrolepiota procera DPPH scavenging activity. 
Hemolysis inhibition; 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
India 
Portugal 
 
Morchella angusticeps  DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Morchella conica Chelating effects on ferrous ions; 
DPPH scavenging activity. 
Hydrogen peroxide scavenging activity; 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay. 
India 
Turkey 
Morchella esculanta Chelating effects on ferrous ions; 
Conjugated diene method. 
DPPH scavenging activity; 
Hydrogen peroxide scavenging activity 
Reducing power;  
Superoxide anion radical scavenging activity. 
Taiwan 
Turkey 
Morchella vulgaris  Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Hydrogen peroxide scavenging activity; 
Reducing power;  
Superoxide anion radical scavenging activity. 
Turkey 
Mycena rosea DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Phellinus linteus CAM assay. 
Chelating ability on ferrous ions. 
Korea 
Serbia 
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Mushroom species Antioxidant Activity Assays Country 
DPPH scavenging activity. 
FAD assay; 
Inhibition of lipid peroxidation; 
TBARS assay; 
Xanthine oxidase inhibition. 
Phellinus rimosus Nitric oxide scavenging activity; 
Superoxide anion radical scavenging activity;  
TBARS assay. 
India 
Picoa juniperi Chelating effects on ferrous ions; 
DETBA method; 
DPPH scavenging activity; 
Hydroxyl radicals scavenging activity; 
Linoleic acid assay; 
Reducing power. 
Spain 
 
Pleurotus citrinopileatus  DPPH scavenging activity. 
Reducing power. 
Taiwan 
 
Pleurotus cystidiosus Chelating effects on ferrous ions; 
DETBA method;  
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity;  
Reducing power. 
Taiwan 
Pleurotus djamor DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Pleurotus eryngii DPPH scavenging activity. Korea 
Pleurotus ostreatus Chelating effects on ferrous ions 
DETBA method; 
DPPH scavenging activity; 
Hydroxyl radicals scavenging activity; 
Linoleic acid assay; 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay; 
Thiocyanate method. 
India 
Korea 
Spain  
Taiwan 
Turkey 
Pleurotus sajor-caju DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Polyporus annosus DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus badius DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus fomentarius DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus gilvus DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus pinicola DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus radiatus DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus squamosus  Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Turkey 
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Mushroom species Antioxidant Activity Assays Country 
Reducing power;  
Superoxide anion radical scavenging activity; 
Thiocyanate method. 
Polyporus stevenii DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus sulphureus DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Polyporus volvatus DPPH scavenging activity; 
Ferrous ion-chelating effect; 
FRAP assay; 
β-carotene bleaching inhibition. 
Turkey 
Ramaria aurea DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Ramaria botrytis  DPPH scavenging activity; 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Russula brevepis  DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Russula cyanoxantha DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Russula delica  
 
Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Reducing power;  
Superoxide anion radical scavenging activity; 
Thiocyanate method; 
β-carotene bleaching inhibition. 
Portugal 
Turkey 
 
Russula olivacea DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal  
Russula vesca DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Sarcodon imbricatus  
 
DPPH scavenging activity; 
Hemolysis inhibition. 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Sparassis crispa DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India  
Korea 
Stropharia rugoso-annulata DPPH scavenging activity; 
Metal chelating activity; 
Reducing power. 
China 
Suillus  granulatus DPPH scavenging activity. Portugal 
Suillus bellini DPPH scavenging activity. Portugal 
Suillus collinitus Chelating effects on ferrous ions; 
DPPH scavenging activity;  
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Turkey 
Suillus granulatus  DPPH scavenging activity. Portugal 
Suillus luteus DPPH scavenging activity. Portugal 
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Mushroom species Antioxidant Activity Assays Country 
Suillus mediterraneensis DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Suillus variegatus DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Terfezia claveryi Chelating effects on ferrous ions; 
DETBA method; 
DPPH scavenging activity. 
Hydroxyl radicals scavenging activity; 
Linoleic acid assay 
Reducing power;  
Spain 
Termitomyces albuminosus Chelating effects on ferrous ions; 
Conjugated diene method; 
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity;  
Reducing power. 
Taiwan 
Termitomyces heimii Chelating effects on ferrous ions; 
DPPH scavenging activity; 
Hydrogen peroxide scavenging activity. 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay. 
India Turkey 
Termitomyces microcarpus  DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Termitomyces mummiformis  DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Termitomyces shimperi DPPH scavenging activity; 
Reducing power;  
TBARS assay. 
India 
Termitomyces tylerance  Chelating effects on ferrous ions; 
DPPH scavenging activity. 
Hydrogen peroxide scavenging activity. 
Reducing power;  
Superoxide anion radical scavenging activity; 
TBARS assay. 
India 
Turkey 
Trametes versicolor Chelating ability on ferrous ions; 
DPPH radical scavenging activity; 
FRAP assay; 
Ferrous ion-chelating effect; 
Inhibition of lipid peroxidation; 
β-carotene bleaching inhibition. 
Serbia Turkey 
 
Trichloma giganteum  Chelating effects on ferrous ions 
DETBA method; 
DPPH scavenging activity;  
Hydroxyl radicals scavenging activity;  
Reducing power. 
Taiwan 
Tricholoma acerbum  DPPH scavenging activity; 
Reducing power;  
TBARS assay; 
β-carotene bleaching inhibition. 
Portugal 
Tricholoma equestre DPPH scavenging activity. Portugal 
Tricholoma sulphureum DPPH scavenging activity; 
Reducing power; 
β-carotene bleaching inhibition. 
Portugal 
Tricholomopsis rutilans DPPH scavenging activity. Portugal 
Verpa conica Superoxide anion radical scavenging activity; 
Reducing power;  
DPPH scavenging activity; 
Chelating effects on ferrous ions; 
Turkey 
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Mushroom species Antioxidant Activity Assays Country 
Thiocyanate method. 
Volvariella volvacea  DPPH scavenging activity: 
Hemolysis inhibition; 
TBARS assay. 
β-carotene bleaching inhibition. 
China 
Xerocomus chrysenteron  Reducing power;  
DPPH scavenging activity; 
Chelating effects on ferrous ions; 
β-carotene bleaching inhibition. 
Turkey 
This table was elaborated based on the information available in the review article (Ferreira et al. 2009) and 
the following references on the same topic published since 2009: Heleno et al., 2010; Sarikurkcu et al., 2010; 
Grangeia et al., 2011; Öztürk et al., 2011; Orhan and Üstün, 2011; Palacios et al., 2011; Kozarski et al., 2012; 
Liu et al., 2012; Pereira et al., 2012; Tiana et al., 2012.  
Over the last decades, natural compounds have drawn a great deal of attention from 
both the scientific community and the general public, as cancer chemopreventive agents 
and also as cancer therapeutics (Nobili et al., 2009).   
Mushrooms comprise a vast and yet largely untapped source of powerful new 
pharmaceutical products. In particular, and most importantly for modern medicine, they 
represent an unlimited source of compounds which are modulators of tumour cell growth. 
Furthermore, they may have potential as functional foods and sources of novel molecules.  
The compounds with antitumour potential identified so far in mushrooms, can be 
classified according to their molecular weight these will include low-molecular-weight 
compounds (LMW, e.g. quinones, cerebrosides, isoflavones, catechols, amines, 
triacylglycerols, sesquiterpenes, steroids, organic germanium and selenium) and high-
molecular-weight compounds (HMW, e.g. homo and heteroglucans, glycans, 
glycoproteins, glycopeptides, proteoglycans, proteins and RNA-protein complexes) 
(Figure 11). 
These compounds have been reported to prevent tumourigenesis and also to suppress 
the growth of established tumours (Fulda, 2010). Particularly, mushrooms with 
potentially useful properties against cancers of the stomach, esophagus, lungs, etc. are 
known in China, Japan, Korea, Russia, United States and Canada (Ferreira et al., 2010). 
Tables 3 and 4, and Figure 11 describe different types of natural compounds isolated  from 
wild mushrooms with antitumoural potential.  
Chapter I. Introduction 
 
 
45 
 
 
Figure 11. Low-molecular-weight (LMW) and high-molecular-weight (HMW) compounds with antitumour 
potential found in mushrooms [adapted from (Ferreira et al., 2010)]. 
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Table 3. Studies on low-molecular-weight compounds with antitumour potential found in wild mushrooms 
[Adapted from (Ferreira et al., 2010)]. 
Mushroom species Antitumour agents Molecular targets 
Agaricus bisporus 490 Quinone (γ-L-glutaminyl-4-hydroxy-2,5-
benzoquinone) (4) 
DNA polymerase α inhibitor 
Selenium DNA cytosine methyltransferase 
inhibitor 
Agaricus blazei Ergosterol (15) Cyclooxygenase inhibitor and 
anti-angiogenic 
Boletus edulis Selenium DNA cytosine methyltransferase 
inhibitor 
Clitocybe clavipes Clavilactones CB (3a), CD (3b) and CA (3c) Tyrosine kinase inhibitors 
Cordyceps sinensis 5,8-Epidioxy-24(R)-methylcholesta-6,22-dien-3β-ol 
(14a) 
Sulfatase inhibitor 
5. 5,8-Epidioxy-24(R)-methylcholesta-6,22-dien-3β-
D-glucopyranoside (14b) 
6. 5,6-Epoxy-24(R)-methylcholesta-7,22-dien-3β-ol 
(14c) 
Not known 
Daedalea dickinsii Polyporenic acid C (24) MMPs inhibitor 
Flammulina velupites Genistein (7) Cdc2 kinase modulator 
Selenium DNA cytosine methyltransferase 
inhibitor 
Fomitella fraxinea Fomitellic acids A and B (26a,b) DNA polymerase α and β 
inhibitors 
Ganoderma 
applanatum 
Ergosta-4,6,8(14),22-tetraen-3-one (16) Cyclooxygenase inhibitor 
Ganoderma lucidum (4E,8E)-N-D-2’-hydroxypalmitoyl-1-O-β-D-
glucopyranosyl-9-methyl-4,8-sphingadienine (6a) 
DNA polymerase α inhibitors 
(4E,8E)-N-D-2’-hydroxystearoyl-1-O-β-D-
glucopyranosyl-9-methyl-4,8-sphingadienine (6b) 
DNA polymerase α inhibitors 
Lucidenic acid O (17a) 
Lucidenic lactone (17b) 
Cerevisterol (18) 
Lucidumol A (19) and B (20a) 
Ganoderiol F (20b) 
Ganodermanondiol (20c) 
Ganodermanontriol (20d) 
Ganoderic acids A (21a), F (21b), H (21c), W (22), X 
(23a), Y (23b), T (23c) 
DNA polymerase α, β and RT 
inhibitors (17a and 17b) 
DNA polymerase α inhibitor (18) 
NF-KB and AP-1 inhibitors (21a 
and 21c) 
DNA topoisomerase inhibitor 
(23a) 
 
Bis-β-carboxyethylgermanium sesquioxide: 
O3(GeCH2CH2COOH)2 
 
Not known 
Ganoderma neo-
japonicum 
Ergosta-4,6,8(14),22-tetraen-3-one (16) Cyclooxygenase inhibitor 
Gerronema Gerronemins A-F (9a-f) COX-2 inhibitors 
Grifola frondosa 1-Oleoyl-2-linoleoyl-3-palmitoylglycerol (12) Cyclooxygenase inhibitor 
Ergosterol (15) Cyclooxygenase inhibitor and 
anti-angiogenic 
Ergosta-4,6,8(14),22-tetraen-3-one (16) Cyclooxygenase inhibitor 
Gymnopilus 
marginatus 
6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (Hispidin) 
(8) 
PKCβ inhibitor 
Gymnopilus 
parvisporus 
6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (Hispidin) 
(8) 
PKCβ inhibitor 
Gymnopilus patriae 6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (Hispidin) 
(8) 
PKCβ inhibitor 
Ionotus hispidus 6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (Hispidin) 
(8) 
PKCβ inhibitor 
Lampteromyces 
japonicus 
Iludin S and M (13a,b) and derivatives The derivatives are DNA-
alkylating agents 
Lentinus crinitus Panepoxydone (1) NF-KB inhibitor 
Lepiota americana 2-aminophenoxazin-3-one (10) Aromatase inhibitor 
5,8-Epidioxy-24(R)-methylcholesta-6,22-dien-3β-ol 
(14a) 
 
Sulfatase inhibitor 
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Mushroom species Antitumour agents Molecular targets 
Omphalotus illudens Iludin S and M (13a,b) and derivatives The derivatives are DNA-
alkylating agents 
Phellinu linteus 6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (Hispidin) 
(8) 
PKCβ inhibitor 
Panus conchatus Panepoxydone (1) NF-KB inhibitor 
Panus rudis Panepoxydone (1) NF-KB inhibitor 
Pholiota spumosa Putrescine-1,4-dicinnamide (11) Not known (inducer of apoptosis 
and necrosis) 
Piptoporus betulinus (E)-2-(4-hydroxy-3-methyl-2-butenyl)-hydroquinone 
(5) 
MMPs inhibitor 
Piptoporus betulinus Polyporenic acid C (24) MMPs inhibitor 
Pleurotus ostreatus Selenium DNA cytosine methyltransferase 
inhibitor 
Poria cocos Dehydroebriconic acid (25) DNA topoisomerase II inhibitor 
Xylaria strain 45-93 Cycloepoxydon (2) NF-KB inhibitor 
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Figure 12. Chemical structure of the low-molecular-weight (LMW) compounds with antitumour potential 
found in mushrooms [Adapted from (Ferreira et al., 2010)]. 
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Table 4. Studies on high-molecular-weight compounds with antitumour potential extracted of wild 
mushrooms [Adapted from (Ferreira et al., 2010)]. 
Mushroom species Antitumour agents Details 
Agaricus bisporus Lectins Immunomodulator and antiproliferative; in 
vitro cell lines 
Agaricus blazei ATOM Immunomodulator; pre-clinical animal models 
AB-FP Immunomodulator; clinical trials 
FA-2-b-Md Immunomodulator; in vitro cell lines 
(16)-β-D-glucan with (13)-β-D 
branches: 
D-fraction 
Immunomodulator; clinical trials (breast, 
prostate, lung, liver, and gastric cancers) 
(16)-β-D-glucan with (14)- α 
branches 
Immunomodulator; pre-clinical animal models 
(13)-α- glucan Immunomodulator; pre-clinical animal models 
(13)-α–glucan with (16)-β 
branches  
Immunomodulator; pre-clinical animal models 
(16)-α–glucan with (14)-α 
branches 
Immunomodulator; pre-clinical animal models 
Mannogalactoglucan Immunomodulator; in vitro cell lines 
Riboglucan Immunomodulator; in vitro cell lines 
Xyloglucan Immunomodulator; pre-clinical animal models 
Glucomannan Immunomodulator; pre-clinical animal models 
Agrocybe aegerita (13)-α- glucan Immunomodulator; pre-clinical animal models 
Amanita muscaria (13)-α- glucan Immunomodulator; pre-clinical animal models 
Armillariella tabescens  Linear (16)- β-D-glucan Immunomodulator; pre-clinical animal models 
(13)-α- glucan Immunomodulator; pre-clinical animal models 
Auricularia auricula Linear (13)-β-D-glucan Immunomodulator; pre-clinical animal models 
Boletus satanas Lectins Immunomodulator and antiproliferative; in 
vitro cell lines 
Clitocybe nebularis Clitocypin Cysteine proteinase inhibitor; in vitro enzymatic 
inhibition assays 
Cryptoporus volvatus H-3-B Immunomodulator; pre-clinical animal models 
Dictyophora indusiata Fucomannogalactan Immunomodulator; pre-clinical animal models 
Dictyophora indusiata Mannan Immunomodulator; pre-clinical animal models 
Flammulina velutipes Flammulin Immunomodulator; in vitro cell lines 
Galactomannoglucan Immunomodulator; pre-clinical animal models 
Riboglucan Immunomodulator; in vitro cell lines 
Fomitella fraxinea Mannofucogalactan Immunomodulator; in vitro cell lines 
Ganoderma lucidum Ganoderans Immunomodulator; in vitro cell lines 
Glycopeptide complexes Immunomodulator; pre-clinical animal models 
GLIS Immunomodulator; pre-clinical animal models 
Protein LZ8 Immunomodulator; pre-clinical animal models 
GLP Immunomodulator; pre-clinical animal models 
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Mushroom species Antitumour agents Details 
Mannogalactoglucan Immunomodulator; in vitro cell lines 
(13)-β-glucuronoglucan Immunomodulator; in vitro cell lines 
Ganoderma tsugae Arabinoglucan Immunomodulator; pre-clinical animal models 
Glucogalactan Immunomodulator; pre-clinical animal models 
Grifola frondosa Lectins Immunomodulator and antiproliferative; in 
vitro cell lines 
Grifolan, GRN  Immuno-enhancing activity; clinical trials 
(gastrointestinal, lung, liver and breast cancers) 
(16)-β-D-glucan with (13)-β-D 
branches: 
D-fraction 
Immunomodulator; clinical trials (breast, 
prostate, lung, liver, and gastric cancers) 
Mannoxyloglucan Immunomodulator; pre-clinical animal models 
Xyloglucan Immunomodulator; pre-clinical animal models 
Fucomannogalactan Immunomodulator; pre-clinical animal models 
Mannogalactofucan Immunomodulator; pre-clinical animal models 
Hericinum erinaceus Galactoxyloglucan-protein complex Immunomodulator; in vitro cell lines 
Glucoxylan Immunomodulator; pre-clinical animal models 
Galactoxyloglucan Immunomodulator; in vitro cell lines 
Xylan Immunomodulator; pre-clinical animal models 
Mannoglucoxylan Immunomodulator; pre-clinical animal models 
Hericium caput-medusae Glucoxylan-protein complex Immunomodulator; in vitro cell lines 
Hohenbuehelia serotina Galactomannoglucan Immunomodulator; pre-clinical animal models 
Inonotus obluquus Xylogalactoglucan Immunomodulator; in vitro cell lines 
Lentinus edodes KS-2 Immunomodulator; in vitro cell lines 
LEM Immunomodulator; pre-clinical animal models 
Lentinan Immuno-enhancing activity; clinical trials 
(gastric, colorectal, prostate and breast cancers) 
Galactoglucomannan Immunomodulator; pre-clinical animal models 
Lentinus lepideus PG101 Immunomodulator; pre-clinical animal models 
Leucopaxillus giganteus Galactomannoglucan Immunomodulator; pre-clinical animal models 
Lyophyllum decastes Linear (13)-β-D-glucan Immunomodulator; pre-clinical animal models 
Lyophyllum decastes Linear (16)- β-D-glucan Immunomodulator; pre-clinical animal models 
Morchella esculenta Galactomannan Immunomodulator; pre-clinical animal models 
Pachyman from Poria 
cocos  
(13)- β-D-glucan with (12) or 
(16) branches 
Immunomodulator; pre-clinical animal models 
Phellinus linteus PL Immunomodulator; pre-clinical animal models 
Pleurotus citrinopileatus Arabinogalactan Immunomodulator; pre-clinical animal models 
Pleurotus cornucopiae Mannogalactoglucan Immunomodulator; in vitro cell lines 
Pleurotus ostreatus Pleuran Immunomodulator; pre-clinical animal models 
Pleurotus pulmonariu Mannogalactoglucan Immunomodulator; in vitro cell lines 
Xyloglucan Immunomodulator; pre-clinical animal models 
Mannogalactan Immunomodulator; in vitro cell lines  
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Mushroom species Antitumour agents Details 
Glucoxylan Immunomodulator; pre-clinical animal models 
Pleurotus tuber-regium Alkali-soluble glucan Immunomodulator; in vitro cell lines 
Polyporus confluens Xyloglucan Immunomodulator; pre-clinical animal models 
Sarcodon aspratus Fucogalactan Immunomodulator; pre-clinical animal models 
Schizophyllum commune Schizophyllan, SPG Immuno-enhancing activity; clinical trials 
(gastric, cervical, head and neck cancers) 
Sclerotinia sclerotiorum Scleroglucan, SSG Immunomodulator; clinical trials 
Sparassis crispa SCG Immunomodulator; pre-clinical animal models 
Trametes versicolor PSP  Immuno-enhancing activity; clinical trials  
PSK or krestin  Immuno-enhancing activity; clinical trials (head, 
neck, upper gastro-intestinal, colorectal, lung , 
and breast cancers) 
Tremella fuciformis Tremellastin 
(Glucuronoxylomannans) 
Immunomodulator; pre-clinical animal models 
Tricholoma lobayense PSPC Immunomodulator; pre-clinical animal models 
Tricholoma mongolicum Lectins Immunomodulator and antiproliferative; in 
vitro cell lines 
Volvariella volvacea Lectins Immunomodulator and antiproliferative; in 
vitro cell lines 
As can be seen in Tables 2, 3 and 4, there are several compounds that might contain 
functional or medicinal properties, which may be used as a source of biologically and 
physiologically active substances. Therefore, it is very important to carry out studies 
concerning the isolation, structural characterization and classification of compounds from 
mushrooms presenting potential antioxidant and antitumoural properties. 
5. FRAMEWORK AND OBJECTIVES 
As previously stated, mushrooms represent a rich source of biologically active 
compounds with recognized potential in drug discovery and development (Harvey, 2000; 
Newman et al., 2000). Mushrooms have been widely used in traditional oriental medicine 
and are a source of compounds with antitumour properties (Ferreira et al., 2010).The 
most important are high-molecular-weight compounds (e.g. polysaccharides, 
glycoproteins, proteoglycans and proteins). Some examples are Krestin (PSK), from the 
cultured mycelium of Coriolus versicolor, Lentinan from the fruiting bodies of Lentinus 
edodes and Schizophyllan from the culture fluid of Schizophyllum commune. Lentinan 
and Schizophyllan are pure β-glucans, whereas PSK is a protein bound polysaccharide. 
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The biological activity of these three products is related to their immunomodulating 
properties, which enhance the body’s defences against various forms of infectious disease 
(Mizuno, 1993; Zaidman et al., 2005), and are being used along with chemotherapy and 
radiotherapy in China, Japan and Korea (Larone, 2002). Furthermore, the anti- prostate 
cancer stem cells effect of PSP (other active component extracted from C. versicolor) was 
demonstrated as being also the chemopreventive property of oral PSP consumption 
against prostate cancer (Luk et al.,. 2011).  
Mushrooms are also rich sources of antioxidant compounds, such as phenolic 
compounds (mainly phenolic acids), followed by tocopherols, ascorbic acid and 
carotenoids (Ferreira et al., 2009).  
Nevertheless, there are many undiscovered mushrooms with possible antioxidant 
properties and tumour cell growth inhibitory activity. The Northeast of Portugal is, due to 
climatic conditions, one of the European regions with higher wild mushrooms diversity, 
some of them with great gastronomic relevance. Mushrooms collection and consumption 
is a traditional practice in this region. In most cases, mushrooms collection is for self-
consumption, despite the risks of this practice. Nevertheless, in the recent years the 
collection of wild mushrooms for commercialisation purposes became intensified, due to 
national and international interest in their nutritional and medicinal properties. 
Therefore, their potential as functional foods and as sources for the development of drugs 
and nutraceuticals should be explored.  
Thus, the specific aims of this work were:  
- Collection and taxonomic identification of species of wild mushrooms from the 
Northeast of Portugal with potential medicinal interest. 
- Preparation of extracts (phenolic and polysaccharidic) from those species and 
evaluation of their bioactive properties: 
o antioxidant properties using different techniques (DPPH radical-
scavenging activity, reducing power, inhibition of β-carotene bleaching) 
and 
o effect on the growth of various human tumour cell lines (NCI-H460 - lung 
cancer, MCF-7 – breast cancer, HCT-15 - colon cancer, AGS - gastric 
cancer). This panel of tumour cell lines has been chosen to represent 
cancers with higher incidence nowadays. 
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- Evaluation of the effects of the most active extracts on cell cycle profile and 
apoptosis. 
- Identification and quantification of some of the compounds related to the 
mentioned bioactivities.  
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1. WORKING PLAN 
The working plan of this thesis is schematized in Figure 16 and was the following: 
1) Collection and identification of mushroom samples. The taxonomic identification 
of sporocarps was made according to the recommendations of several authors 
(Marchand, 1971; Marchand, 1986; Bon, 1988; Courtecuisse and Duhem, 2005).  
2) Extraction of the samples in order to obtain phenolic (rich in low molecular weight 
compounds) and polysaccharidic (rich in high molecular weight compounds) 
extracts. The samples were submitted to solid-liquid extractions using different 
solvents (methanol, ethanol and boiling water).  
3) Chemical characterization of the extracts: 
a. phenolic compounds were analysed by high performance liquid 
chromatography coupled to a photodiode array detector (HPLC-DAD); 
b. sugars were determined, after polysaccharides hydrolysis, by high 
performance liquid chromatography coupled to a refraction index detector 
(HPLC-RI) using raffinose or fructose as internal standards (IS);  
c. the nutritional value of some species (when not previously reported in 
literature) was also evaluated. 
4) Evaluation of antioxidant potential:   
a. DPPH radical-scavenging activity assay – DPPH is a radical of nitrogen 
which is synthetic and highly stable because of the delocalization  of the 
free electron, responsible for the deep purple color characteristic of this 
molecule. DPPH reacts with compounds which are capable of donating a 
hydrogen atom and reducing it, with the formation of a pale yellow 
compound (hydrazine) (Antolovich et al. 2002; Amarowicz et al., 2004); 
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Figure 13. Reduction of DPPH radical (2,2-Diphenyl-1-picrylhydrazyl). 
 
 
b. Reducing power assay- This assay measures the capacity of a given 
antioxidant reducing Fe(III)/ferricyanide [FeCl3/K3Fe(CN)6] to Fe(II) 
(Berker, 2007). Thus, the yellow color of the solution is changed to 
Prussian blue, depending on the concentration of the antioxidant present 
in the solution. The reduction reaction takes place according to the 
following equations:  
K3FeCN6
pH=6,6
→     3K+ + Fe(CN)6
3− 
 
Fe(CN)6
3−⏟    + antioxidant
                         
→         Fe(CN)6
4− + oxidated antioxidant 
                  Yellow 
Fe(CN)6
4− Fe3+  
                       
→        Fe[Fe(CN)6]⏟         
                                           Prussian Blue 
Figure 14. Reactions involved in the reducing power assay. 
 -  
                                                                    
 
 
c. Inhibition of -carotene bleaching assay. The antioxidant activity of the 
extracts was evaluated by the -carotene linoleate model system (Mi-Yae et 
al., 2003). This assay is based on spectrophotometric measurement of 
bleaching of the β-carotene, evaluating the scavenging activity on free 
radicals generated during the peroxidation of linoleic acid. The test is 
according to the following equations: 
β− carotene − H(laranja) + ROO ∙ 
                
→      β − carotene ∙ (bleached) + ROOH 
 
N
N
NO2
NO2O2N
antioxidant
N
NH
NO2
NO2O2N
Violet    Yellow   
.
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β− carotene − H(orange) + ROO ∙  +AH 
                   
→       β− carotene − H(orange) + ROOH + A ∙  
Figure 15. Reactions involved in the inhibition of β-carotene bleaching assay. 
 
This mechanism is involved in bleaching carotenoids by a thermal 
oxidation, which can be reduced by the action of the antioxidants in the 
sample (Amarowicz et al., 2004; Kaur et al., 2006). Thus, the decrease of 
the orange color of β-carotene is inversely proportional to the amount of 
antioxidants present in the extracts. 
5)  Screening for potential tumour cell growth inhibitors. The effects of the extracts on 
the growth of human tumour cell lines was evaluated, according to the procedure 
adopted in the NCI’s in vitro anticancer drug screening, which uses the 
sulforhodamine B (SRB) assay to assess cell growth inhibition (Skehan et al., 1990). 
This colorimetric assay estimates cell number indirectly, by staining cellular protein 
with the protein-binding dye SRB. 
6) Selection of the most active extracts: ethanolic extract of Clitocybe alexandri in NCI-
H460 cell line and methanolic extract of Suillus collinitus in MCF-7 cancer cell line. 
7) Chemical characterization of compounds in the most active extracts. 
8) Study of the effect of the most active extracts, and of their individual compounds, in 
the cell cycle distribution and in cellular apoptosis, by flow cytometry. 
9) Finally, evaluation of the effect of the most active extracts on the levels of expression 
of some proteins involved in cell cycle and/or apoptosis (p53,p21, Bcl2, XIAP,PARP) 
by Western blotting.   
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Figure 16. Schematic representation of the working plan. 
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2. EXPERIMENTAL 
This section describes the author contributions to the technical procedures used in 
each experimental methodology which was conducted for this thesis. The experimental 
methods are described in the five papers (Annexes I - V) which form an integrated part of 
this thesis.  
Collection and taxonomic identification of mushrooms from the 
Northeast of Portugal 
All the samples were collected in different ecosystems of the Northeast of Portugal 
and taxonomically identified with the technical support of Prof. Anabela Martins, as 
described in the experimental part of Annexes I-V.  
Preparation of mushrooms phenolic and polysaccharidic extracts  
Phenolic and polysaccharidic extracts were obtained performing solid-liquid 
extractions with different solvents: methanol/ethanol and boiling water, respectively, at 
CIMO (Laboratory of Applied Chemistry and Biochemistry), as described in the 
experimental part of Annexes I - V.  
Chemical characterization  
The extracts were further characterized using High-Performance Liquid 
Chromatography (HPLC) coupled with different detectors: diode array (DAD) and 
refraction index (RI) detectors for phenolic compounds and sugars analysis, respectively, 
at CIMO (Laboratory of Applied Chemistry and Biochemistry), as described in the 
experimental part of Annexes I, II and V .  
Antioxidant activity assays 
The antioxidant activity assays (DPPH radical-scavenging activity, reducing power 
and inhibition of -carotene bleaching) were performed at CIMO (Laboratory of Applied 
Chemistry and Biochemistry), as described in the experimental part of Annexes I, III and 
V.  
Trypan blue exclusion assay 
The Trypan blue exclusion assays were performed on four solid tumour cell lines: 
NCI-H460 (non-small cell lung cancer), MCF-7 (breast cancer), AGS (gastric cancer), 
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HCT-15 (colon cancer). This work was carried out at IPATIMUP (Cancer Drug Resistance 
Group), as described in the experimental part of Annex IV.  
Sulphorhodamine B assay 
The sulphorhodamine B (SRB) assay was performed on two leukemia cell lines, K562 
and HL-60, and on four solid tumour cell lines: NCI-H460 (non-small cell lung cancer), 
MCF-7 (breast cancer), AGS (gastric cancer), HCT-15 (colon cancer). This work was 
carried out at IPATIMUP (Cancer Drug Resistance Group), as described in the 
experimental part of Annexes III and V. Some of the analyses were conducted with the 
technical support of Dr. Gabriela Almeida, Catarina Tavares or Diana Ferreira. 
Flow Cytometry 
Analysis of the cell cycle profile and apoptosis levels were performed by flow 
cytometry, at IPATIMUP (Cancer Drug Resistance Group), as described in the 
experimental part of Annexes IV and V. Some of the assays were conducted with the 
technical support of Dr. Gabriela Almeida. 
Western Blotting 
Western blots were performed at IPATIMUP (Cancer Drug Resistance Group), as 
described in the experimental part of Annexes IV and V. Some of the assays were 
conducted with the technical support of Dr. Gabriela Almeida or Catarina Tavares. 
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1. SAMPLES COLLECTION, IDENTIFICATION AND NUTRITIONAL 
CHARACTERIZATION 
Thirty five samples (Table 5) were collected in different ecosystems (Quercus 
pyrenaica, Pinus pinaster, Pinus sylvestris Ait and mixed stands) of the Northeast of 
Portugal in the period from autumn 2007 until spring 2012.  
The morphological identification of the wild macrofungi was made according to 
macro and microscopic characteristics (Marchand, 1971; Marchand, 1986; Bon, 1988; 
Courtecuisse and Duhem, 2005; Moreno, 2005) and online keys 
(http://www.mycokey.com/).  
Representative voucher specimens were deposited at the herbarium of Instituto 
Politécnico de Bragança. After taxonomic identification, the mushrooms were immediately 
lyophilized (Ly-8-FM-ULE, Snijders, Holland). 
The nutritional composition of Armillaria mellea, Calocybe gambosum, Clitocybe 
odora, Coprinus comatus, Hygrophorus agathosmus, Hygrophorus olivaceo-albus, 
Russula caerulea and Tricholoma atrosquamosum was performed in this work (Annex 1), 
while the other species were previously studied (Table 5). 
  
 
Table 5. Information about the wild edible mushroom species collected identified and analyzed. 
Species Kingdom Division Class Order Family Genus Reference Ecology Ref. 
Agaricus arvensis Fungi Basidiomycota Agaricomycetes Agaricales Agaricaceae Agaricus L.:Fr. emend 
Karst. 
Saprotrophic Barros et al., 
2007 
Agaricus bisporus Fungi Basidiomycota Agaricomycetes Agaricales Agaricaceae Agaricus L.:Fr. emend 
Karst. 
Saprotrophic Barros et al., 
2008a 
Armillaria mellea Fungi Basidiomycota Agaricomycetes Agaricales Physalacriaceae Armillaria (Vahl) P. 
Kumm. 
Parasitic Determined 
herein  
(Annex  1) 
Boletus edulis Fungi Basidiomycota Agaricomycetes Boletales Boletaceae Boletus Bull. (1782) Mycorrhizal Barros et al., 
2008a 
Calocybe gambosum Fungi Basidiomycota Agaricomycetes Agaricales Lyophyllaceae Calocybe (Fr.) Donk Mycorrhizal Determined 
herein 
(Annex  1) 
Cantharellus cibarius 
(comercial) 
Fungi Basidiomycota Agaricomycetes Cantharellales Cantharellaceae Cantharellus Adans. ex Fr. Mycorrhizal Barros et al., 
2008a 
Canthrelus cibarius 
(Silvestre) 
Fungi Basidiomycota Agaricomycetes Cantharellales Cantharellaceae Cantharellus Adans. ex Fr. Mycorrhizal Barros et al., 
2008b 
Clitocybe alexandri Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Clitocybe (Gillet) 
Konrad 
Saprotrophic Heleno et al., 
2010 
Clitocybe odora Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Clitocybe (Fr.) P. Kumm Mycorrhizal Determined 
herein 
(Annex  2) 
Coprinus comatus Fungi Basidiomycota Agaricomycetes Agaricales Agaricaceae Coprinus (O.F.Müll.) 
Pers.  
Saprotrophic Determined 
herein 
(Annex  1) 
Craterellus 
cornucopioides 
Fungi Basidiomycota Agaricomycetes Cantharellales Cantharellaceae Craterellus (L.) Pers. Saprotrophic Barros et al., 
2008a 
Fistulina hepatica Fungi Basidiomycota Agaricomycetes Agaricales Fistulinaceae Fistulina (Schaeff.) 
With.  
Parasitic Heleno et al., 
2009 
Flammulina velutipes Fungi Basidiomycota Agaricomycetes Agaricales Phisalacriaceae Flammulina (Curt.: Fries) 
Singer 
Saprotrophic Reis  et al., 
2012 
Hydnum repandum  Fungi Basidiomycota  Agaricomycetes Cantharellales Hydnaceae Hydnum (L.: Fr.) Mycorrhizal Heleno et al., 
2010 
Hygrophorus 
aurantiaca 
Fungi Basidiomycota Agaricomycetes Boletales Hygrophoropsidacea
e 
Hygrophoropsi
s 
(Wulfen) 
Maire 
Mycorrhizal Heleno et al., 
2010 
Hygrophorus 
agathosmus 
Fungi Basidiomycota  Agaricomycetes Agaricales Hygrophoraceae Hygrophorus (Fr.) Fr. Mycorrhizal Determined 
herein 
(Annex  2) 
Hygrophorus olivaceo-
albus 
Fungi Basidiomycota  Agaricomycetes Agaricales Hygrophoraceae Hygrophorus Fr. (Fr.) Mycorrhizal Determined 
herein 
(Annex  2) 
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Laccaria amethystina Fungi Basidiomycota Agaricomycetes Agaricales Hydnangiaceae Laccaria (Huds.) Cooke Mycorrhizal Heleno et al., 
2010 
Laccaria laccata Fungi Basidiomycota Agaricomycetes Agaricales Hydnangiaceae Laccaria (Scop.) Cooke Mycorrhizal Heleno et al., 
2009 
Lactarius deliciosus Fungi Basidiomycota Agaricomycetes Russulales Russulaceae Lactarius (L. ex Fr.) 
S.F.Gray 
Mycorrhizal Barros et al., 
2007 
Lactarius salmonicolor Fungi Basidiomycota Agaricomycetes Russulales Russulaceae Lactarius (L. ex Fr.) 
S.F.Gray 
Mycorrhizal Heleno et al., 
2009 
Lepista inversa Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Lepista (Scop.) Pat Saprotrophic Heleno et al., 
2009 
Lepista nuda Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Lepista (Bull.) Cooke Saprotrophic Barros et al., 
2008b 
Leucopaxillus 
giganteus 
Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Leucopaxillus (Sowerby) 
Singer 
Saprotrophic Barros et al., 
2007 
Lycoperdon molle Fungi Basidiomycota Agaricomycetes Agaricales Agaricaceae Lycoperdon Pers. Saprotrophic Barros et al., 
2008b 
Marasmius oreades Fungi Basidiomycota Agaricomycetes Agaricales Marasmiaceae Marasmius (Bolton) Fr Saprotrophic Barros et al., 
2008a 
Ramaria botrytis Fungi Basidiomycota Agaricomycetes Gomphales Gomphaceae Ramaria (Pers.) Ricken  Mycorrhizal Barros et al., 
2008b 
Russula caerulea  Fungi Basidiomycota  Agaricomycetes Russulales Russulaceae Russula (Pers) Fr. Mycorrhizal Determined 
herein 
(Annex  2) 
Russula delica Fungi Basidiomycota Agaricomycetes Russulales Russulaceae Russula Fr. Mycorrhizal Heleno et al., 
2009 
Sarcodon imbricatus Fungi Basidiomycota Agaricomycetes Thelephorales Bankeraceae Sarcodon (L.) P. Karst. Mycorrhizal Barros et al., 
2007 
Suillus collinitus Fungi Basidiomycota Agaricomycetes Agaricales Suillaceae Suillus (Fr.) Kuntze Mycorrhizal Heleno et al., 
2010 
Suillus luteus Fungi Basidiomycota Agaricomycetes Agaricales Suillaceae Suillus (L.: Fries) 
Gray 
Mycorrhizal Reis et al., 
2011a 
Suillus 
mediterraneencis 
Fungi Basidiomycota Agaricomycetes Agaricales Suillaceae Suillus (Jacquet & J. 
Blum) 
Redeuilh 
Mycorrhizal Heleno et al., 
2009 
Tricholoma 
atrosquamosum  
Fungi Basidiomycota  Agaricomycetes Agaricales Tricholomataceae Tricholoma  (Cheval) sacc. Mycorrhizal Determined 
herein 
(Annex  2) 
Tricholoma imbricatus Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Tricholoma Fr Mycorrhizal Heleno et al., 
2009 
Tricholoma 
portentosum 
Fungi Basidiomycota Agaricomycetes Agaricales Tricholomataceae Tricholoma (Fr.) Quél. Mycorrhizal Barros et al., 
2007 
  
 
2. PHENOLIC PROFILE OF THE WILD EDIBLE MUSHROOMS 
Protocatechuic, p-hydroxybenzoic, p-coumaric and cinnamic acids were identified 
and quantified in the analysed samples (eighteen edible species) by comparing their 
chromatographic characteristics and absorption spectra with that of the standard 
compounds (Tables 2, Annexes 1 and 2). The other species were chemically characterized 
by Barros et al. (2007).  Fistulina hepatica showed the highest concentration of phenolic 
acids (111.72±7.19 mg/Kg dw), mostly due to the contribution of protocatechuic and p-
hydroxybenzoic acids. Therefore, this indicats that mushrooms have developed chemical 
defence mechanisms (against insects and microorganisms) analogous to those that have 
been observed in plants, such as the production of phenolic compounds. In fact, phenolic 
compounds have been shown to protect the plant cell wall during UV, salt, or pathogenic 
stress (Signore et al., 1997; Lattanzio et al., 2006). 
Other authors (Ribeiro et al., 2007) reported the presence of caffeic, p-coumaric and 
ellagic acids in F. hepatica collected in the same region (Bragança, Portugal) in 2004. 
However, we did not find any of those phenolic compounds in our sample. Instability in 
the phenol content over time after mushroom collection is often observed, probably due to 
enzymatic and oxidative decomposition. This fact, together with the different stress 
conditions to which the mushrooms were submitted, as well as the different extraction 
methodologies applied (in addition to possible genetic variability), could explain the 
differences observed between the present study and other studies, in what concerns the 
phenolic profile of  F. hepatica (Ribeiro et al., 2007) and Hydnum repandum (Puttaraju et 
al., 2006).  
In addition, in a study from our group, it was possible to detect and quantify cinnamic 
acid in a Portuguese sample of H. repandum, while other authors also quantified tannic, 
gallic and protocatechuic acids in a sample of this mushroom collected in/ India 
(Puttaraju et al., 2006). 
No phenolic acids were detected in Laccaria amethystina, Lepista inversa and 
Russula delica. Nevertheless, Yaltirak and collaborators (2009) found gallic acid, 
catechin, caffeic acid and rutin in a sample of R. delica from Turkey. These authors used 
an extraction methodology with ethanol in a soxhlet apparatus at 60ºC. We avoided using 
heat due to the fact that phenolic compounds are unstable and readily become non-
antioxidative under heating conditions and in the presence of antioxidants (Yen and 
Hung, 2000; Barros et al., 2007a). However, the results obtained by Yaltirak and 
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collaborators (2009) support the view that heat may increase the concentration in 
phenolics.  
In addition, Choi and collaborators (2006) described that heat treatment of Shiitake 
increased the overall content in free polyphenolic and flavonoid compounds. The authors 
explained that heat treatment might produce changes in their extractability due to the 
disruption of the plant cell wall e thus bound polyphenolic and flavonoid compounds may 
be released more easily, relative to those from raw materials. 
Antioxidants and particularly phenolic compounds may decrease the risks of several 
chronic diseases such as atherosclerosis, cancer, diabetes, aging and other degenerative 
diseases in humans (Halliwell, 1996). Overall, F. hepatica revealed the highest 
concentration in phenolic compounds. The phenolic profile of this sample and of a sample 
of H. repandum and R. delica has already been described (Yaltirak et al., 2009; Puttaraju, 
et al., 2006). 
However, we pointed out some differences between our results and the results 
obtained by those authors; Puttaraju and collaborators (2006) found in H. repandum, 
collected in India, tannic acid, gallic acid, protocatechuic acid and cinnamic acid and we 
only identified cinnamic acid. Yaltirak and collaborators (2009) identified in R. delica 
from Turkey the following phenolic compounds: gallic acid, catechin caffeic acid and rutin. 
Furthermore, our work describes for the first time the identification of phenolic 
compounds in fourteen other mushroom species.  
The edible mushrooms could be directly used in the human diet as nutritional foods 
to combat oxidative stress, taking advantage on the possible synergistic and/or additive 
effects of all the compounds present therein (Liu, 2004). On the other hand, inedible 
species could represent a source of extractable phenolic compounds to be used as 
additives in the food industry or as components in pharmaceutical and/or cosmetic 
formulations, due to their well-known antioxidant properties. 
Several phenolic compounds were previously identified and quantified in wild 
mushrooms from Finland, India, Korea and Portugal (Ferreira et al., 2009) but not in the 
herein studied species. To the best of our knowledge, this is the first report of the presence 
of individual phenolic compounds in A. mellea, C. gambosa, C. odora and C. comatus. 
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3. ACTIVITY ANTIOXIDANT ACTIVITY OF AQUEOUS, ETHANOLIC 
AND METHANOLIC EXTRACTS OF WILD EDIBLE MUSHROOMS 
The antioxidant activity of Armillaria mellea, Calocybe gambosa, Clitocybe odora, 
Coprinus comatus, Clitocybe alexandri, Lepista inversa and Suillus collinitus was 
evaluated using radical species generated in the reaction system, such as DPPH radicals 
(DPPH scavenging activity assay) and linoleate-free radical (β-carotene bleaching 
inhibition assay), or by using  the reducing effect on Fe3+/ferricyanide complex (reducing 
power assay).  
The water soluble polysaccharidic fractions revealed a higher antioxidant activity than 
the ethanolic fractions, except for C. comatus (Table 1, Annex 1). Moreover, the ethanolic 
fraction of A. mellea, C. gambosa, C. odora and C. comatus species showed the highest 
DPPH radical scavenging activity (EC50 value 2.56 mg/ml; extract concentration that 
causes 50% of antioxidant activity) (Table 2, Annex 1).  This observation is in agreement 
with its higher content in phenolic compounds, compared to the other studied 
mushrooms.  The ethanolic fraction studied here gave better results (reducing power 1.61 
at 5 mg/ml; DPPH scavenging activity 79.92% at 5 mg/ml, data not shown) than the 
ethanolic extracts (reducing power 0.45 at 5 mg/ml; DPPH scavenging activity 84.5% at 5 
mg/ml) or the hot water extracts (reducing power 0.25 at 5 mg/ml; DPPH scavenging 
activity 58.9% at 20 mg/ml) previously obtained by other authors from C. comatus 
collected in Taiwan (Tsai et al., 2007). 
The water soluble polysaccharidic fraction of C. odora showed the lowest EC50 value 
regarding reducing power (0.94 mg/ml) and β-carotene bleaching inhibition (0.27 
mg/ml). The ethanolic fraction of C. gambosa showed higher EC50 values (i.e., lower 
antioxidant activity) than a commercial sample previously studied by some elements of 
our group (7.14 mg/ml, 4.31 mg/ml and 2.77 mg/ml for DPPH scavenging activity, 
reducing power and b-carotene bleaching inhibition, respectively). Nevertheless, that 
sample, previously studied by some elements involved in this thesis, was a crude 
methanolic extract obtained at room temperature (Queirós et al., 2009) and was not 
produced following the fractionated procedure with boiling water and ethanol, such as the 
one used in the present work.  
The ethanolic extracts of L. inversa and C. alexandri gave higher antioxidant activity 
(lower EC50 values; Table 1, Annex 3) than the methanolic extracts, which is in agreement 
with the highest content in phenolics found in the first extracts. Nevertheless, it was the 
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polysaccharidic extracts that revealed the most potent antioxidant activity in the three 
studied assays (EC50 < 2.5 mg/ml). 
The methanolic extract of S. collinitus revealed the lowest antioxidant activity (highest 
EC50 values) in all the assays. The antioxidant properties of ethanolic and boiled water 
extracts of S. collinitus were similar (without significant statistical differences), except for 
reducing power which was higher in the ethanolic extract (1.3 mg/ml; Table 2, Annex 5). 
The observed antioxidant potential might be related to the phenolic acids found (Table 1, 
Annex 5) and their reported chemoprotective effects against oxidative stress-mediated 
disorders, mainly their free radical scavenging and metal chelating properties (Soobrattee 
et al., 2005). 
4. TUMOUR CELL GROWTH INHIBITORY ACTIVITY OF THE 
AQUEOUS, ETHANOLIC AND METHANOLIC EXTRACTS OF WILD 
EDIBLE MUSHROOMS 
The effect of the extracts on the growth of four human tumour cell lines was 
evaluated, according to the procedure adopted in the NCI’s in vitro anticancer drug 
screening, which uses sulforhodamine B (SRB) assay to assess cell growth inhibition. This 
was carried out for thirty five (35) wild edible mushroom extracts (methanolic, ethanolic 
and boiling water extracts). Results are expressed as GI50 (concentrations of extracts that 
cause 50% cell growth inhibition). These studies were conducted in four human tumour 
cells lines, selected as being representative of lung, breast, colon and gastric cancer. 
The majority of the extracts did not reveal any growth inhibitory potential in tumour 
cell lines, up to the highest concentration tested (400 µg/ml, Table 6). 
Table 6. Effects of the mushroom extracts on the growth of human tumour cell lines. Results are expressed 
as the average GI50 (in µg/ml) of a minimum of 3 independent experiments (except when GI50 > 400µg/ml, 
in which case a minimum of  2  independent experiments were carried out). 
Species Extracts NCI-H460 MCF-7 HCT-15 AGS 
(lung cancer) (breast 
cancer) 
(colon 
cancer) 
(gastric 
cancer) 
Agaricus 
arvensis 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Agaricus Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
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Species Extracts NCI-H460 MCF-7 HCT-15 AGS 
(lung cancer) (breast 
cancer) 
(colon 
cancer) 
(gastric 
cancer) 
bisporus Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Armillaria 
mellea 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Boletus edulis Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Calocybe 
gambosum 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Cantharellus 
cibarius 
(comercial) 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Canthrelus 
cibarius 
(Silvestre) 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Clitocybe 
alexandri 
Phenolic (methanolic) 34.8 ± 2.8 
µg/ml 
34.2 ± 1.4 
µg/ml 
36.9 ± 3.1 
µg/ml 
36.1 ± 2.3 
µg/ml 
Phenolic (ethanolic)  24.8 ± 
2.3µg/ml 
17.9 ± 1.3 
µg/ml 
21.7 ± 2.3 
µg/ml 
26.0 ± 1.3 
µg/ml 
Polysaccharidic (boiling water) 24.5 ± 1.8 
µg/ml 
46.8 ± 1.6 
µg/ml 
59.1 ± 0.7 
µg/ml 
51.7 ± 0.9 
µg/ml 
Clitocybe 
odora 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Coprinus 
comatus 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Craterellus 
cornucopioides 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Fistulina 
hepatica 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Flammulina 
velutipes 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Hygrophorus 
aurantiaca 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Lacaria 
amethystina 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Laccaria Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
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Species Extracts NCI-H460 MCF-7 HCT-15 AGS 
(lung cancer) (breast 
cancer) 
(colon 
cancer) 
(gastric 
cancer) 
laccata Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Lactarius 
deliciosus 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Lactarius 
salmonicolor 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Lepista inversa Phenolic (methanolic) 36.3 ± 5.1 
µg/ml 
45.2 ± 3.1 
µg/ml 
39.7 ± 4.6 
µg/ml 
67.4 ± 5.5 
µg/ml 
Phenolic (ethanolic)  118.3 ± 2.5 
µg/ml 
79.1 ± 11.8 
µg/ml 
42.3 ± 4.5 
µg/ml 
58.5 ± 3.3 
µg/ml 
Polysaccharidic (boiling water) 155.0 ± 3.5 
µg/ml 
137.4 ± 1.3 
µg/ml 
77.4 ± 5.5 
µg/ml 
99.9 ± 7.8 
µg/ml 
Lepista nuda Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Leucopaxillus 
giganteus 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Lycoperdon 
molle 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Marasmius 
oreades 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Marasmius 
oreades 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Ramaria 
botrytis 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Russula delica Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Sarcodon 
imbricatus 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Suillus 
collinitus 
Phenolic (methanolic) 62.5 ± 6.3 
µg/ml 
25.2 ± 0.16 
µg/ml 
103.2 ± 9.9 
µg/ml 
79.2 ± 15.5 
µg/ml 
Phenolic (ethanolic)  253.7 ± 2.3 
µg/ml 
101.8 ± 8.9 
µg/ml 
139.4± 34.1 
µg/ml 
170.7 ± 35 
µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Suillus luteus  Phenolic (methanolic) 30.3± 1.1 
µg/ml 
32.3 ± 5.7 
µg/ml 
17.8 ± 1.6 
µg/ml 
30.33 ± 3.1 
µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Chapter III. Results and Discussion 
 
 
77 
 
Species Extracts NCI-H460 MCF-7 HCT-15 AGS 
(lung cancer) (breast 
cancer) 
(colon 
cancer) 
(gastric 
cancer) 
Tricholoma 
gambosum 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Tricholoma 
imbricatus 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Tricholoma 
portentosum 
Phenolic (methanolic) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Phenolic (ethanolic)  > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Polysaccharidic (boiling water) > 400µg/ml > 400µg/ml > 400µg/ml > 400µg/ml 
Note: This is the only table presented in the results and discussion section,  since  it contains unpublished data. All the 
other obtained results are presented in the Annexes. 
The mushroom species that revealed cell growth inhibitory activity against at least 
some of the studied human tumour cell lines were: Clitocybe alexandri, Lepista inversa, 
Suillus collinitus and Suillus luteus.  
Indeed, the phenolic (methanolic and ethanolic) and the polysaccharidic (boiling 
water) extracts from C. alexandri and L. inversa revealed capacity to inhibit 50% of the 
growth of all the human tumour cell lines studied, when used in concentrations lower than 
160 µg/ml. C. alexandri was more potent than L. inversa in inhibiting the growth of the 
four studied human tumour cell lines. For C. alexandri, the lowest GI50 values were 
generally obtained with the ethanolic extracts, while for L. inversa, methanolic extracts 
proved to be generally more potent, with the exception of the AGS cells (in which the more 
potent extract was the ethanolic). For both mushrooms, the polysaccharidic extract was 
usually the less potent one (Table 2, Annex 3). 
Regarding the S. collinitus, the methanolic extract was the most potent of the tested 
extracts in all the tested cell lines, presenting GI50 values ranging from 25.2 to 103.2 µg/ml 
in MCF-7 and HCT-15 cells, respectively. The boiled water extract did not show any effect 
on the tested cell lines at the studied concentrations (up to 400 µg/ml). The MCF-7 cell 
line was the most susceptible (i.e. presented the lowest GI50) to the S. collinitus methanolic 
extract (Table 3, Annex 5). 
Regarding S. Luteus, the methanolic extract was the only one that inhibited cell 
growth in all the cell lines tested and up to the maximum concentration tested (up to 400 
µg/ml). The HCT-15 cell line was the most susceptible (presented the lowest GI50) to this 
extract (Table 6). 
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5. THE CLITOCYBE ALEXANDRI ETHANOLIC EXTRACT AND THE 
SUILLUS COLLINITUS METHANOLIC EXTRACT IN CELL CYCLE 
AND APOPTOSIS IN LUNG AND BREAST CANCER CELL LINES, 
RESPECTIVELY 
Two of the most active samples, Clitocybe alexandri ethanolic extract and Suillus 
collinitus methanolic extract, were chosen to be further investigated regarding some 
elucidation of their possible mechanism of action. 
Regarding the C. alexandri ethanolic extract 
The NCI-H460 cell line was incubated with the GI50 (24.8 µg/ml) or 2×GI50 (49.6 
µg/ml) concentrations of the C. alexandri ethanolic extract, for 48 h, and the effects of this 
extract on the normal cell cycle distribution and induction of apoptosis were studied.  
The analysis of the effect of the ethanolic extract of C. alexandri on the cell cycle 
profile was performed by flow cytometry. Results show a dose-dependent increase in the 
percentage of cells in the S-phase of the cell cycle, with a concomitant decrease in the 
percentage of cells in the G1 and G2/M phases (Figure 1, Annex 4). Therefore, the C. 
alexandri extract seems to be an inducer, in these non-small cell lung cancer cells, of an 
increase in the percentage of cell in the S-phase of the cell cycle following 48 h of 
treatment.  
Additionally, it was investigated whether C. alexandri induced apoptosis in the NCI-
H460 cell line, by the annexin V-FICT/PI flow cytometry assay. NCI-H460 cells treated 
with twice the GI50 concentration of the ethanolic extract of C. alexandri for 48 h 
presented a significant increase in the percentage of apoptotic cells (28.6% ± 0.9%), when 
compared to the blank (untreated) cells (6.6% ± 0.3%).Nonetheless, cells treated with the 
GI50 concentration of the extract for 48 h only presented 7.3% ± 2.1% of apoptotic cells 
(similar to the blank treatment i.e. similar to untreated cells).  
Furthermore, the effect of this C. alexandri mushroom extract on the expression of 
some proteins involved in the apoptotic process was determined by Western blot. Results 
showed that treatment of NCI-H460 cells with the GI50 concentration of the extract for 
48h caused an increase in the levels of wt p53, cleaved caspase-3 and cleaved PARP 
(Figure 2, Annex 4), consistent with apoptotic cell death. 
Chapter III. Results and Discussion 
 
 
79 
 
Regarding the S. collinitus methanolic extract 
The MCF-7 cell line was incubated with the GI50 (25.2 µg/ml) or twice the GI50 (50.4 
µg/ml) concentrations of the S. collinitus methanolic extract,  for 48 h, and the effect of 
this treatment on the normal cell cycle distribution and induction of apoptosis were 
studied, by flow cytometry.  
The results show that both the GI50 concentration and 2×GI50 concentration of this 
extract increased the number of cells in the G1 phase of the cell cycle and concomitantly  
decreased the percentage of cells in the S phase of the cell cycle (Figure 2, Annex 5). 
Additionally, it was investigated whether S. collinitus methanolic extract induced 
apoptosis in the MCF-7 cell line, using the annexin V-FICT/PI flow cytometry assay. MCF-
7 cells treated with the methanolic extract of S. collinitus for 48 h presented an increase in 
the percentage of apoptotic cells, from 6.0±0.2% in untreated (blank) cells, to 15.3±2.0% 
in cells treated with the GI50 concentration and to 16.3±2,0 % in  cells treated with 2×GI50 
concentration.  
Furthermore, the effect of this mushroom extract on the expression of some proteins 
involved in the cell cycle and/or apoptotic process was determined, by Western blot. 
Results show that treatment of MCF-7 cells with the GI50 concentration of the extract 
caused a strong increase in the levels of p53. This effect was even stronger when cells were 
treated with 2×GI50 concentration, suggesting that the effect is concentration-dependent. 
Accordingly, the levels of p21, whose expression is regulated by p53 and related to cell 
cycle progression, were also increased in a concentration dependent manner (with the GI50 
and with the 2× GI50 concentrations).  Finally, treatment of these cells with the extract 
caused a decrease in the levels of XIAP and Bcl-2 and a concentration-dependent increase 
in the levels of cleaved PARP, which is consistent with an apoptotic process of cell death 
(Figure 4, Annex 5). 
The effect of treating MCF-7 cells concomitantly with S. collinitus (methanolic 
extract) and etoposide was also studied, by verifying the % of cell growth upon a 48 h 
incubation with the previously determined approximate GI50 concentration of etoposide (1 
µM) and with the GI50 (25.2 µg/ml) of the extract. The combined use of the methanolic 
extract and etoposide caused a greater  reduction in the % of cell growth, when compared 
to either of them used individually, indicating the potential benefit of this combination 
(Figure 5, Annex 5).  
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6. CYTOTOXIC POTENTIAL IN TUMOUR CELL LINES OF SOME 
PHENOLIC ACIDS IDENTIFIED IN THE MOST ACTIVE WILD 
EDIBLE MUSHROOMS 
The in vitro cell growth inhibitory activity of the compounds (protocatechuic, p-
hydroxybenzoic, and cinnamic acids) identified in the two most active wild mushrooms (C. 
alexandri and S. collinitus) was evaluated with the SRB assay, after a continuous 
treatment of NCI-H460 cells during 48 h with these compounds.  
Cinnamic acid was found to be the most potent compound regarding cell growth 
inhibition even though the GI50  was quite high (GI50 value 845.9 ± 97.5 µM) (Figure 4, 
Annex 4).  
Protocatechuic acid revealed a GI50 value of 1616.9 ± 75.3 µM, while p-hydroxybenzoic 
acid did not show any activity up to the highest tested concentration (3000 µM) (Figure 4, 
Annex 4).  
The effect of the individual and combined treatment with these identified compounds 
was also tested, by verifying the number of viable cells upon a 48 h incubation with the 
GI50 concentrations of cinnamic and protochatequic acids and 3000 µM of p-
hydroxibenzoic acid (the maximum concentration tested in the SRB, since the GI50 was 
not obtained even with this high concentration). Results were compared with those 
obtained with DMSO control and blank treatment (i.e. cells incubated with complete 
medium). Treatment with the GI50 concentration of cinnamic and protochatequic acids 
caused a reduction in the number of viable cells up to ≈ 50 %, as expected to occur with 
the GI50 concentration of any compound (Figure 5, Annex 4).In addition, p-
hydroxibenzoic acid did not cause any a significant reduction in the viable cell number, as 
expected from the results previously obtained with the SRB assay.  
In addition, it was verified that the concomitant use of the three compounds provided 
the strongest decrease in the viable number of NCI-H460 cells, suggesting a potential 
concomitant effect of those compounds (Figure 5, Annex 4). 
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Among the 35 wild edible mushrooms collected in the Northeast of Portugal and properly 
identified, 114 extracts (phenolic and polysaccharidic) were prepared for analysis of 
antioxidant activity and/or cell growth inhibitory activity in tumour cell lines. None of 
these species had ever been studied with regard to the latter activity. Three species 
revealed growth inhibitory activity in the studied human tumour cell lines (NCI-H460 - 
lung cancer, MCF-7 -breast cancer, HCT-15 -colon cancer and AGS - gastric cancer): C. 
alexandri ethanolic extract, L. inversa methanolic extract and S. collinitus methanolic 
extract. 
The most susceptible cell lines were NCI-H460 for C. alexandri (GI50 26.0 ± 1.3 
µg/ml) and MCF-7 S. collinitus (GI50 25.2 ± 0.16 µg/ml) extracts. 
C. alexandri ethanolic extract induced an S-phase cell cycle arrest and increased the 
percentage of apoptotic cells, in the NCI-H460 cell line. 
S. collinitus methanolic extract induced a slight increase in the number of cells in G1, 
with a concomitant decrease in the percentage of cells in the S phase of the cell cycle and 
an increase in the percentage of apoptotic cells, in the MCF-7 cell line. 
The combined use of the S. collinitus methanolic extract and etoposide (a known 
cytotoxic drug used in the treatment of some cancers) caused a greater decrease in the 
percentage of cell growth, when compared to either of them used individually, indicating 
the potential benefit of this combination. 
The analysed mushroom species also provided interesting antioxidant potential, 
mainly the polysaccharidic extract of L. inversa which showed the highest DPPH radical 
scavenging activity, reducing power and β-carotene bleaching inhibition.  
The tested extracts were chemically characterized and protocatechuic, p-
hydroxybenzoic, p-coumaric and cinnamic acids were the main compounds identified on 
the phenolic (methanolic and ethanolic) extracts, while mannitol, trehalose and arabinose 
were the main sugars found in the polysaccharidic (boiling water) extracts after hydrolysis.  
The individual compounds identified in the extracts were submitted to a screening of 
tumour cell growth inhibitory activity, but only the phenolic acids and a related 
compound, cinnamic acid, presented some (although modest) activity. This compound 
was found to be the most potent studied one, regarding cell growth inhibition in the NCI-
H460 cell line.   
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The effect of the individual and combined treatment with the identified phenolic 
compounds was also evaluated. Treatment with the GI50 concentration of cinnamic and 
protochatequic acids caused a statistically significantly reduction in the number of viable 
cells (up to ≈50%), as expected to occur with the GI50 concentration of any compound. In 
addition, p-hydroxybenzoic acid did not show any significantly reduction in the viable cell 
number, as expected from the results previously obtained with SRB assay. Nevertheless, it 
was verified that the concomitant use of the three compounds provided the strongest 
decrease in the viable cell number, suggesting a possible concomitant effect of those 
compounds. 
In conclusion, the results obtained in this thesis help to clarify the bioactive potential 
of wild edible mushrooms from the Northeast of Portugal. This study allowed to identify 
some species with antioxidant or tumour cell growth inhibitory potential. Nonetheless, 
more studies are needed to be carried out in order to elucidate the mechanism of action of 
the best extracts and the contribution of each of the identified molecules towards the 
observed phenotype. In addition, the isolation of more compounds from these extracts 
and their further study regarding these activities needs to be carried out.  
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ANNEX 1 - CHEMICAL COMPOSITION OF WILD EDIBLE MUSHROOMS AND 
ANTIOXIDANT PROPERTIES OF THEIR WATER SOLUBLE POLYSACCHARIDIC AND 
ETHANOLIC FRACTIONS.  
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ANNEX 2 - PHENOLIC PROFILE OF SEVENTEEN PORTUGUESE WILD MUSHROOMS.  
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ANNEX 3 - WILD MUSHROOMS CLITOCYBE ALEXANDRI AND LEPISTA INVERSA: IN 
VITRO ANTIOXIDANT ACTIVITY AND GROWTH INHIBITION OF HUMAN TUMOUR 
CELL LINES. 
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ANNEX 4 - CLITOCYBE ALEXANDRI EXTRACT INDUCES CELL CYCLE ARREST AND 
APOPTOSIS IN A LUNG CANCER CELL LINE: IDENTIFICATION OF PHENOLIC 
ACIDS WITH CYTOTOXIC POTENTIAL. 
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ANNEX 5 - SUILLUS COLLINITUS METHANOLIC EXTRACT INCREASES P53 
EXPRESSION AND CAUSES CELL CYCLE ARREST AND APOPTOSIS IN A BREAST 
CANCER CELL LINE 
 
 
 
